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SUMMARY
Daily variations in plasma (PcAMP), urine (UcAMP), 
nephrogenous cAMP (NcAMP) and hormones known to affect cAMP 
metabolism were studied. Circadian variations in PTH (1- 
84) and NcAMP were observed. Both increased significantly 
overnight and early morning. PcAMP and glucagon decreased 
overnight and following meals. PcAMP had greater
fluctuations over 24h than glucagon indicating several 
hormones have transient effects on PcAMP production.
A 7h shift of the sleep-wake cycle moved sleep-associated 
prolactin secretion but caused minimal alteration in PTH 
(1-84) . NcAMP secretion overnight decreased, suggesting 
PTH (1-84) end organ responses may be modified by other 
hormones and effectors when sleep is disturbed. PcAMP 
decreased overnight reaching a nadir corresponding to the 
lowest glucagon concentration. PcAMP fluctuations were 
greater when compared to normal 24h profiles.
Following a 96h fast serum phosphate, PTH (1-84) and NcAMP 
circadian rhythms were attenuated. Mean serum calcium and 
NcAMP production were significantly decreased. Fasting 
increased variability in PTH (1-84) secretion which may be 
an important signalling mechanism inducing bone resorption. 
Serum phosphate fluctuations may play an important role in 
the genesis of PTH (1-84) and NcAMP circadian rhythms. 
Mean glucagon concentration was increased with attenuation 
of the circadian rhythm and mean PcAMP concentration 
increased. Dissociation of bone and kidney effects of PTH 
(1-84) in fasting may be due to acute acidosis.
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In 1°HPT the concerted overnight increase in PTH (1-84) and 
NcAMP was absent. Parathyroid adenoma resection restored 
phosphate, PTH (1-84) and NcAMP circadian rhythms. The 
phosphate increase may stimulate PTH (1-84) secretion which 
then influences the phosphate rhythm. Mean PcAMP was 
increased in 1°HPT but 24h PcAMP profiles differed little 
pre and post surgery.
24h studies indicate control of the circadian rhythms of 
PTH (1-84), NcAMP and PcAMP is complex. Several hormones 
act in concert to regulate cAMP generation and end organ 
responses.
Thyrotoxic patients had mean PTH (1-84) and NcAMP lower 
than normals, hypothyroid and treated hypothyroid patients. 
Increased serum calcium decreases PTH (1-84) and 
subsequently NcAMP in thyrotoxicosis. In hypothyroid 
patients PTH (1-84) and NcAMP are dissociated with mean PTH 
(1-84) increased compared to thyrotoxic patients but NcAMP 
remained similar to euthyroid subjects indicating 
resistance to PTH (1-84). Thyroxine treated patients have 
mean PTH (1-84) concentrations lower than euthyroid 
controls with a relatively increased NcAMP. PcAMP is 
increased in thyrotoxic and thyroxine treated patients and 
decreased in hypothyroid patients.
Synacthen increased PcAMP with the pattern similar to the 
cortisol profile. This was either due to simultaneous
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release of cAMP and cortisol following adrenal stimulation 
or was a direct effect of cortisol. Dexamethasone 
decreased NcAMP and UcAMP with a variable effect on PcAMP. 
Variability in the PcAMP response is probably due to 
combined effects of dexamethasone and cortisol whereas 
decreased UcAMP and NcAMP production may represent altered 
kidney cell sensitivity to PTH (1-84) caused by decreased 
cortisol.
In 1°HPT patients a significant correlation between PTH (1- 
84) and NcAMP exists (r=0.66, pcO.OOl). A subgroup of 
1 °HPT patients have NcAMP inappropriately high for the 
measured PTH (1-84) . Two patients had increased PTHrP but 
in the majority PTHrP was low and the discrepancy was 
unexplained. In three patients PcAMP concentration was 
lower than expected. Twelve 1°HPT patients, divided 
equally, received atenolol or placebo and were studied 
prospectively for 6 months. No significant effect of 
atenolol on any parameter was observed.
In patients with Paget's disease treated with 
bisphosphonate (APD) calcium decreased, PTH (1-84) and 
NcAMP increased significantly. Patients with HCM prior to 
therapy with APD had a suppressed or low PTH (1-84) . A 
high percentage had elevated NcAMP indicating the presence 
of a circulating humoral factor, probably PTHrP, causing 
hypercalcaemia. APD therapy in HCM patients resulted in a 
significant reduction in serum calcium. No patient
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developed significant hypocalcaemia. PTH (1-84) secretion 
was stimulated as serum calcium decreased and PTH (1-84) 
was detectable or elevated whilst some patients remained 
hypercalcaemic. The absolute concentration rather than 
rate of decrease of serum calcium was more important in 
regulating PTH (1-84) secretion. NcAMP correlated poorly 
with PTH (1-84) in treated HCM patients. An increase then 
decrease in NcAMP was observed associated with a decrease 
then increase in TmP04 indicating PTHrP may increase 
transiently following APD therapy.
PTHrP measurement confirmed the hormone's role in the 
aetiology of HCM and a strong correlation of PTHrP with 
NcAMP. In HCM patients with breast, lung and kidney 
malignancy PTHrP secretion commonly results in elevated 
NcAMP. Patients with HCM and haematological,
gastrointestinal and ear-nose-throat malignancies have low 
circulating PTHrP and normal or low NcAMP. Squamous cell 
carcinomas commonly secrete PTHrP. 78% of normals had 
detectable PTHrP which may reflect sample collection into 
protease inhibitor tubes, age distribution of the normal 
population, assay sensitivity and properties of the assay 
antibodies. Alternatively the assay may be subject to non­
specific binding effects or matrix effects. A subgroup of 
patients was detected with low PTHrP and low PTH (1-84) 
with inappropriate or elevated NcAMP. These patients may 
be producing a factor which stimulates NcAMP production. 
This factor (s) may be a fragment of PTHrP or PTH not
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recognised by the IRMAs or may be a new molecule causing 
hypercalcaemia mediated via cAMP.
Superfusion of rat renal tubules was used to study cAMP 
production in response to PTH stimulation. Optimal 
conditions producing a consistent, reproducible cAMP 
response were identified. Tubules were equilibrated on 
columns for 90 min, prior to stimulation with 2.5 units 
bovine PTH (1-84) at 10 min intervals. A significant 
decrease in cAMP production in response to PTH was observed 
when tubules were perfused with buffer acidic (pH 7.1) 
relative to normal physiological pH (pH 7.4). Perfusion 
with buffer relatively alkalotic (pH 7.65) had no 
significant effect on PTH stimulated cAMP production. 7mM 
arginine hydrochloride in the perfusate significantly 
decreased cAMP production. Superfusion of rat renal 
tubules was a reliable, reproducible method for studying 
the action of PTH.
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Chapter 1
Introduction and Literature Review
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1.1 Cellular Control of Cyclic Adenosine 3'.5' 
Monophosphate Production: Historical Perspective to
Current Belief
Cyclic adenosine 3',5' monophosphate (cyclic AMP, cAMP) was 
first identified in biological systems by Sutherland and 
Rail (1958) (1) whilst studying hormone dependent
glycogenolysis in liver cells. Sutherland and co-workers 
(1962) (2) subsequently discovered the enzyme responsible
for the formation of cAMP from adenosine triphosphate 
(ATP), adenylate cyclase (EC. 4.6.1.1) and proposed the 
concept that extracellular hormones were "first messengers" 
and cAMP was a "second messenger" in the information 
transfer process of some endocrine pathways. This "second 
messenger" was generated intracellularly and mediated the 
effects of hormones, which did not themselves enter the 
cell, by activation of intracellular protein kinases (3,4) .
The specificity of the response resides firstly in the 
presence of a particular hormone receptor on the cell 
surface and secondly on the presence of a specific protein 
kinase substrate, usually an enzyme, within the cell (5).
Cell surface receptors are coupled to the adenylate cyclase 
catalytic component through two classes of guanine- 
nucleotide binding proteins (G proteins). Gs stimulates 
adenylate cyclase in response to PTH, TSH, gonadotrophins, 
ACTH, GHRH, /3-adrenergic agonists and many other hormones 
or neurotransmitters (Table 1). Gi mediates inhibition of
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adenylate cyclase in response to a-adrenergic agonists, 
muscarinic agonists, somatostatin and opiate or opiate like 
molecules (Table 1) . The G proteins are heterotrimers, 
consisting of an a-subunit and a tightly coupled jSy-dimer. 
A model for G-protein action has been developed which 
revolves around the unique functional characteristics of 
each G-protein. Binding of an agonist to a stimulatory 
receptor facilitates the exchange of guanine triphosphate 
(GTP) for guanine diphosphate (GDP) in the guanine- 
nucleotide-binding site of Gsa. This results in the 
release of Gsa from the receptor and its dissociation into 
free Gsa-GTP and free By-dimer. Free Gsa-GTP stimulates 
adenylate cyclase activity and thereby increases the 
synthesis of the intracellular second-messenger cAMP. 
Hydrolysis of GTP to GDP by the intrinsic GTPase of Gsa 
enables reassociation of Gsa-GDP with the /Sy-dimer, thus 
restoring Gs to its inactive state. Gs can now re­
associate with the receptor and participate in another 
cycle. GTPase activity functions as a molecular switch 
which regulates the duration of adenylate cyclase activity 
resulting from the formation of the Gsa-GTP complex. After 
a preset time, determined by the kinetics of the GTPase 
activity, Gsce is turned off by the hydrolysis of GTP to 
GDP. This summary of the current theory of G-protein 
function is the summation of many years of postulation and 
investigation (6,7,8,9,10,11,12,13).
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G Protein
Table 1
Adenylate Cyclase 
Stimulatory
Gs
ACTH
A2-Adenosine 
jS-Adrenergic 
Calcitonin 
CRH
Dx-Dopamine
FSH
GHRH
Glucagon
H2-Histamine
LH
MSH
Prostacyclin
PTH
Secretin
S2-Serotonin
TSH
VIP
Receptors coupled to
Adenylate Cyclase 
Inhibitory
Gi
A1 -Adenosine 
a2 -Adrenergic 
D2-Dopamine 
Enkephalin (M,K,E) 
Muscarinic (M2M3) 
Somatostatin
adenylate cyclase mediated
through G proteins
The catalytic activity of adenylate cyclase is influenced 
in intact cells, via the G-proteins, by hormones and 
antibodies (14,15). Broken cell preparations have also 
been used to study adenylate cyclase activity and several 
activators and effectors have been identified. Such 
studies of adenylate cyclase activity only partially 
reflect the properties of the enzyme observed from studies 
of intact cells. Only ATP and magnesium (Mg2+) are required 
for the expression of basal enzyme activity (16) . A 
divalent cation is essential for activity and under normal 
circumstances this is Mg2+ (17,18,19,20). Monovalent 
cations have minimal effects on activity with the exception 
of Lithium (Li+) which can inhibit adenylate cyclase 
activity (21,22,23). Sodium fluoride (NaF) stimulates 
activity (2,24) although this is not observed to any extent 
in whole cell preparations (25). Forskolin significantly 
stimulates adenylate cyclase activity by interacting with 
the catalytic subunit at the internal face of the cell 
membrane structure. Forskolin activation of adenylate 
cyclase has been shown to occur in a significant number of 
endocrine cell types and is a standard means of 
investigating cAMP dependent pathways (26).
Phosphodiesterase (EC. 3.1.4.17) present in most tissues, 
rapidly hydrolyses cAMP to an inactive metabolite adenosine 
5' monophosphate (5'AMP) and phosphoprotein phosphatases 
inactivate protein substrates by dephosphorylation thus 
ensuring the transient nature of the cAMP signal within the
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cell. Phosphodiesterase (PDE) enzymes are found in both 
the cytosol and membrane fractions of the cell and are 
usually classified in terms of their differing affinities 
for the hydrolysis of cAMP (27,28,29). The Km for PDEI to 
cAMP is in the range of 1CT5 M, whereas PDEII, which is 
thought to be predominantly membrane bound, has a Km value 
of 10"6 M (25) . These enzymes are also Mg2+ dependent and 
can be inhibited by divalent cation binders such as 
ethylene-diamine-tetracetic acid (EDTA) and ethylene- 
glycol-tetracetic acid (EGTA) (30). Methylxanthine- 
derivatives are a group of important inhibitors of PDE 
activity and this property is seen medically and socially 
following the ingestion of theophylline and caffeine 
respectively. A very potent methylxanthine-derivative is 
isobuthylmethyl-xanthine (IBMX) which is widely used as a 
PDE-inhibitor under experimental conditions especially when 
studying cellular responses to hormones in-vitro. IBMX is 
particularly useful because unlike several other 
methylxanthines it has very little inhibitory activity on 
adenylate cyclase. Intracellular calcium and calmodulin 
are known to activate PDE (31,32,33) and there is some 
evidence that they can also activate adenylate cyclase (34) 
which suggests that co-ordinate regulation of cAMP 
production can occur through these two effectors.
Once cAMP is generated it exerts its regulatory effects 
through activation of intracellular protein kinase enzymes 
(3,4) . These in turn phosphorylate a number of
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intracellular substrates and the specificity of the cAMP 
signal depends on the substrate availability within the 
cell (5). The phosphorylation may result in activation of 
an enzyme important in a metabolic pathway and may also 
inhibit another enzyme which would have opposite metabolic 
effects, eg glycogen phosphorylase and glycogen synthase in 
liver cells. Termination of such signals is accomplished 
by dephosphorylation of proteins by phosphoprotein- 
phosphatase (4,35,36,37). This enzyme is itself regulated 
by cAMP as has been shown in skeletal muscle where 
activation of cAMP-dependent protein kinase phosphorylates 
a phosphatase inhibitory protein (3 7). This protein binds 
to and temporarily inhibits the activity of the 
phosphoprotein phosphatase which otherwise would 
immediately dephosphorylate and reverse the phosphorylation 
reactions stimulated by cAMP. There is thus a cycle of 
phosphorylation/dephosphorylation which appears to be a 
widespread intracellular regulatory system and ensures 
exquisite control over the cAMP signal.
An ever increasing number of hormones have been shown to 
use cAMP as their "second messenger" (Table 1) . The 
majority of these hormones exert a net catabolic effect on 
their target tissues. Other characteristics are that they 
activate cells very rapidly, within seconds or minutes, 
with a dose-response relationship and have been termed 
immediate hormones in contrast to permissive hormones whose 
cellular effects are only fully expressed about one hour or
37
more after the hormones reach their target cells (38). The 
amount of cAMP generated within a target cell is a 
reflection of hormone receptor interaction and is dependent 
on the concentration of hormone present in the 
extracellular fluid and the number of cell surface 
receptors. Steady state concentrations of cAMP give 
minimal information about hormone action but serial 
measurement after hormonal stimulation can give important 
information on the initial steps of hormone action. Early 
studies measuring cAMP in isolated cells, cell membranes or 
extracellular fluids resulted in valuable information on 
the control of cAMP production, action, release and pointed 
the way to the clinical usefulness of cAMP measurements. 
Although many hormones act via an increase in intracellular 
cAMP a certain basal formation of cAMP occurs in most cell 
systems, independent of the level of immediate hormones in 
the local environment. Alteration of this basal formation 
of cAMP can be observed in growth phases (decrease) and 
when contact inhibition of cell growth occurs (increase) 
(39) . These observations highlight the fact that under 
such in-vitro conditions all synthesis of cAMP is not 
necessarily mediated through hormonal stimulation.
The concentration of cAMP in the intracellular fluid is far 
greater than that in the extracellular fluid (40) . The 
efflux of cAMP from some cells is enhanced by hormone 
receptor interaction. In 1971 Exton et al (40) were the 
first to demonstrate in the isolated perfused liver that
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glucagon was required in the perfusate for the release of 
cAMP into the effluent. Increasing concentrations of 
glucagon resulted in a dose dependent increase in cAMP and 
glucose production with the extracellular cAMP rising 
before measurable elevations of intracellular cAMP. This 
led to the theory of two pools of cAMP with one tightly 
bound and inactive, the other being freely diffusible and
open to hormonal regulation (40). Changes in the
extracellular concentration of cAMP are therefore deemed to 
reflect the net effects of hormonal stimulation on tissue 
cAMP production.
1.2 Phvsiolocrv and Early Clinical Studies
In clinical practice the extracellular fluids that are most 
readily available are plasma and urine. The relatively 
high concentration of cAMP in urine and the ease with which 
individual or serial specimens can be obtained has made 
urine a useful fluid for clinical studies. Measurement of 
cAMP in human urine was first made by Butcher and
Sutherland (1962) (41) and early work confirmed that under 
basal conditions cAMP was present in urine at micromolar 
concentrations (42,43,44). Physiological studies in the 
late 1960s and 1970s, largely pioneered by Broadus and his 
colleagues, demonstrated that the mechanism of renal plasma 
clearance of cAMP was glomerular filtration but that de 
novo production of cAMP also occurred in the kidney. 
Detailed studies with radioactive cAMP tracers (45)
established the basis for the currently accepted mechanism
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of total urinary cAMP (UcAMP) production (46) which is 
summarised in Figure 1. The total amount of cAMP excreted 
in the urine is the sum of that derived from two sources: 
a) the nucleotide filtered at the glomerulus and b) the 
nucleotide produced by the renal tubule. The term 
nephrogenous cAMP (NcAMP) was introduced to describe the 
latter component. Under basal conditions each component 
accounts for approximately 50% of the total quantity of 
cAMP excreted in the urine of normal individuals. Thus 
factors which affect both the plasma concentration and the 
renal production of cAMP can contribute to UcAMP and renal 
function will also influence plasma cAMP (PcAMP) and UcAMP 
concentrations.
In normal subjects virtually every cell in the body 
contributes to the PcAMP concentration with no single 
tissue known to be of particular importance at rest. A 
variety of tissues contribute to metabolism of PcAMP and 
only one-fifth of the metabolic clearance of PcAMP is 
accounted for by excretion in the urine (47). Cyclic AMP 
distributes into a space several fold larger than the 
extracellular volume and turns over rapidly, with a half 
life of approximately 25 min and a metabolic clearance rate 
of about 650 ml/min. It is recognised that physiological 
variations in PcAMP may not be reflected in total UcAMP but 
pharmacological doses of certain hormones and hormonal 
concentrations in disease states can increase PcAMP with a 
resultant increase in total UcAMP.
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SOURCES
CIRCULATING
KIDNEY
OUTPUT
Plasma 
Cyclic AMP
Total Urinary 
Cyclic AMP
Extracellular Cyclic AMP
Nephrogenous 
Cyclic AMP
Filtered 
Cyclic AMP
Figure 1 The production of urinary cAMP
The hormones that have the greatest effects on PcAMP in 
pharmacological doses are adrenaline (48,49,50), glucagon 
(49,51,52,53), parathyroid hormone (PTH) (43,54,55) and 
calcitonin (49,56,57). The increases in UcAMP were 
significant but relatively small in comparison to the rise 
in PcAMP following calcitonin, glucagon and adrenaline but 
a pronounced increase in UcAMP was observed following PTH 
administration.
Studies using renal cortical preparations demonstrated that 
PTH can stimulate the release of cAMP from renal cortical 
tissue (58) . The absence of an increase in PcAMP after PTH 
administration in anephric patients (54) confirmed the 
kidney as the source of the increase in both PcAMP and 
UcAMP in response to PTH. Early reports suggested that 
calcitonin (59,60) and arginine vasopressin (AVP) 
(42,61,62) were able to increase NcAMP. However, it has 
been shown that the effects of calcitonin on NcAMP are 
mediated by secondary rises in PTH (46,63) and the action 
of AVP on NcAMP has not been confirmed (47,49,64) . The 
experimental evidence available confirms the importance of 
PTH in the generation of UcAMP with PTH accounting for 90- 
95% of NcAMP and some 45-50% of total UcAMP in normal man.
1.3 Urinary/Nephrogenous cyclic AMP and Parathyroid 
Function
Measurement of UcAMP is useful in investigating disorders 
of calcium metabolism and provides an assessment of
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parathyroid function (46). Several studies have reported
that UcAMP is elevated in patients with primary
hyperparathyroidism and lowered in patients with
hypoparathyroidism (44,49,61,63,65). However, considerable
overlap between normals and hyperparathyroid patients
existed especially in mild hyperparathyroidism (66).
Improved discrimination between the groups can be achieved
by expressing UcAMP as a function of glomerular filtrate
(GF), as given by :
Urinary cyclic AMP x Serum creatinine 
Urinary creatinine
which provides a parametric index of UcAMP and overcomes
the problems associated with mild to moderate renal
impairment, changes in creatinine excretion in prolonged
illness and differences in creatinine excretion in males
and females (46). The best discrimination between normals
and hyperparathyroidism is achieved when both plasma and
UcAMP are measured which enables NcAMP, expressed per litre
of glomerular filtrate, to be calculated as:
Urinary cyclic AMP x Serum creatinine - Plasma cyclic AMP 
Urinary creatinine
(46,67,68).
The relationship between NcAMP and parathyroid function has 
been elegantly reviewed by Broadus (47) . NcAMP values 
range from near zero to more than 150 nmol/L GF. Typical 
values obtained in hypoparathyroid (2.9 ± 1.6),
hyperparathyroid (44.8 ± 17.0) and euparathyroid subjects 
(3.4-27.0 nmol/L GF) clearly demonstrate that NcAMP
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measurements enable the confident assessment of parathyroid 
activity. Confirmation of the work of Broadus has been 
obtained by other authors (69,70) and in general an overlap 
of NcAMP with normals is obtained in 7-9% of 
hyperparathyroid patients and 3-10% of hypoparathyroid 
patients.
1.4 Urinary/Nephrogenous cyclic AMP in Malignant Disease
Elevation of UcAMP is not specific for hyperparathyroidism 
and interest has centred on the elevation of UcAMP in 
patients with malignant disease. Since patients with 
hypercalcaemia associated with malignancy (HCM) 
characteristically have suppressed PTH concentrations UcAMP 
and NcAMP would be expected to be low in HCM. A number of 
authors have reported elevations of UcAMP and/or NcAMP in 
patients with malignant disease and this finding is most 
frequently observed in patients with hypercalcaemia 
associated with malignancy (47,71,72,73,74). In these 
studies it was observed that patients with squamous cell 
carcinoma of the lung and uro-genital carcinoma were more 
likely to have an increased UcAMP or NcAMP while patients 
with carcinoma of the breast or haematological malignancies 
tended to have normal or low UcAMP and or NcAMP excretion 
(74,75) . It was postulated (74) that patients with 
hypercalcaemia associated with malignancy (HCM) could be 
subdivided into two groups depending on whether their NcAMP 
values were increased or decreased. Those with increased 
NcAMP had few or no bone metastases and those with low or
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decreased NcAMP invariably had widespread skeletal invasion 
by tumour. These results suggested that in patients with 
HCM measurements of NcAMP can be used to detect humoral 
hypercalcaemia of malignancy (HHM) when NcAMP values were 
high and that low NcAMP values were associated with local 
osteolytic hypercalcaemia. In patients with low or 
undetectable plasma PTH and elevated UcAMP or NcAMP it was 
postulated that a tumour derived humoral factor was 
produced with actions similar to PTH (74,76,77,78). 
Subsequently a peptide has been isolated from tumours which 
has remarkable sequence homology at its amino terminal with 
PTH (79,80,81). As a result of similarities in structure 
and function with PTH it has been named parathyroid hormone 
related protein (PTHrP). Measurements of UcAMP and or 
NcAMP with plasma PTH can be used to indicate, indirectly, 
the presence of PTHrP. Differential diagnosis of 
hypercalcaemia based on UcAMP or NcAMP excretion alone is 
not possible, however, since considerable overlap of 
results exists between hyperparathyroidism and HCM (71,82).
1.5 Cyclic AMP in Pseudohypoparathyroidism
In 1942 Albright and colleagues described a syndrome 
characterised by mental deficiency, fits, tetany, dwarfism, 
shortened metacarpals, soft tissue calcification with 
hypocalcaemia and hyperphosphataemia (83) . The cause of 
this syndrome is a combination of separate defects in the 
target-cell response to PTH, end organ resistance. Early 
observations were based on the failure of these patients to
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respond to infusions of PTH extract by increasing the 
fractional excretion of phosphate (84) but this test 
remained unreliable even when purified preparations of PTH 
became available. It was demonstrated that the urine 
excretion of cAMP in response to intravenous PTH was 
markedly decreased in patients with pseudo­
hypoparathyroidism (44) and the test was further modified 
by Tomlinson et al in 1976 who showed that the PcAMP 
response to PTH is also impaired (85). Measurement of the 
urinary phosphate excretion response to PTH is still of 
diagnostic value. Two types of pseudohypoparathyroidism 
are now recognised. Type 1 is characterised by an absence 
of both the increase in UcAMP and phosphate in response to 
PTH and in Type 2 patients have a normal cAMP response to 
PTH but a subnormal phosphaturic response (86).
1.6 Measurement of cyclic AMP
It is clear from the preceding review that measurement of 
UcAMP is mainly useful in metabolic studies but it can 
supply information of clinical value in well defined 
conditions. Several assays exist for the measurement of 
cAMP and in selecting particular methods for use in the 
following experimental work it has been necessary to 
consider the problems presented by each method, the 
expertise and the facilities available to perform the 
method.
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The earliest assays were based on enzymatic methods and 
were time consuming, insensitive, highly dependent on 
enzyme purity and prone to interference (25,87,88,89). 
Competitive protein binding assays were developed based on 
the binding of unlabelled and radioactive cAMP to cAMP 
dependent protein kinase obtained from muscle or adrenal 
cortex (90,91). These methods have a far greater 
sensitivity than enzyme methods and are able to measure 
cAMP in the picomolar range. There is some debate, 
however, about interferences in these assay systems. 
Feinglos et al (92) in a review of cAMP methodologies 
concluded that cAMP binding proteins present in plasma 
interfered and that proteins present in ileal secretions 
also interfered in the assay. Other authors have not found 
such interferences with various fluids, including plasma 
and urine (93,94) .
A major breakthrough in cAMP assays occurred when Steiner 
et al (95) raised antibodies in guinea pigs towards 
succinylated cAMP conjugated to human serum albumin. 
Native cAMP exhibits sufficient cross reactivity with the 
antibodies to succinylated cAMP that the antibodies could 
be used in a radioimmunoassay for cAMP. This method was 
sensitive enough to measure cAMP in the picomolar range. 
The sensitivity of this assay can be increased by 
acetylation or succinylation of the cAMP in the sample 
prior to analysis (96). Acetylation yields a more stable 
product than succinylation, is easy to perform and results
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in an assay capable of measuring femtomole amounts of cAMP. 
Such sensitivity is not usually required when measuring 
urine and plasma but is often necessary when measuring 
tissue extracts, cell culture supernatants or tissue 
perfusates.
RIAs for cAMP have been developed that are sensitive, 
precise, accurate and convenient to use. Assays can also 
be modified in-house so that they are targeted to measure 
cAMP at the concentration of interest in a particular 
sample type. As a result of these assay characteristics 
the vast majority of current research involving measurement 
of cAMP is conducted using RIAs.
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Chapter 2
Technical Methods
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2.1 Biochemical Methods
2.1.1 Cyclic Adenosine Monophosphate
cAMP was measured in urine, which was collected in sterile 
containers using no preservatives, using an in-house 
radioimmunoassay (RIA) which was developed at the Institute 
of Biochemistry and utilises rabbit antibody to cAMP kindly 
donated by Dr B Williams, Department of Medicine, Western 
General Infirmary, Edinburgh. A full evaluation of this 
assay, in thesis format, was submitted to the Royal College 
of Pathologists as part of the final examination for 
membership of the College (97). The assay has a detection 
limit of 2.6 nmol/L (22% CV as defined by Ekins (98)) and 
between-assay CV <10% over the working range of the assay 
(10-150 nmol/L). The rabbit anti-cAMP antiserum was raised 
against an 0-2'-succinyl cAMP-albumin conjugate. The % 
cross reactivities, based on the concentration causing 50% 
displacement, are: cyclic guanosine 3 6 ' -monophosphate
0.25%, adenosine <0.025%, guanosine <0.025%, 5'-adenosine
monophosphate <0.025%, 5'-guanosine monophosphate <0.025%, 
adenosine diphosphonate <0.025% and adenosine triphosphate 
<0.025%. Separation was performed by using donkey anti- 
rabbit antibody (Scottish Antibody Production Unit, Law 
Hospital, Carluke) coupled to Sepharose (99) . The 
sensitivity of this assay can be increased 1000 fold by 
acetylation of samples. This is performed by adding 15 /xL 
of triethylamine and acetic anhydride mixture (ratio 2:1) 
to 500 /xL of sample and vortexing immediately prior to
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assay.
cAMP was measured in plasma after appropriate dilution 
using a commercial RIA supplied by Amersham International 
(Aylesbury, Bucks). Blood is collected into EDTA anti­
coagulant, separated within 3 0 min and stored frozen
(-70°C) prior to analysis.
2.1.2 Parathyroid Hormone
In the majority of studies the intact PTH (PTH (1-84) ) 
molecule was measured in serum using an in-house 
immunoradiometric (IRMA) assay developed at the Institute 
of Biochemistry, Glasgow. The assay utilises two mouse 
monoclonal antibodies to PTH directed at the N and C
terminal ends of the PTH molecule. A full evaluation of 
the assay has been published (100) . The assay has a
sensitivity of 0.5 pmol/L (22% CV) (98) and a CV <10% 
across the range 1.5-250 pmol/L. Quantitative recovery of 
PTH (1-84) standard is obtained (mean recovery 107%) and 
the assay is unaffected by a 200 molar excess of C-terminal 
fragments (PTH (53-84)). A reference range of 1.0-5.0 
pmol/L has been established for this assay.
PTH (1-84) was measured in one study (Chapter 8) using the 
Nichols Institute (San Juan Capistrano) Allegro PTH (1-84) 
IRMA. This assay has a claimed sensitivity of 0.1 pmol/L, 
based on precision in counting small amounts of bound 
radioactivity and an inter assay CV from 5.6% to 6.1% for
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replicate measurements of control sera (control A 3.0-5.3, 
mean 4.2 and control B 23.6-39.3, mean 31.5 pmol/L). Mean 
recovery of PTH (1-84) is 100% and the assay is unaffected 
by 3 00 molar excess of the synthetic peptides PTH (1-34), 
PTH (39-68), PTH (53-84), PTH (44-68) and PTH (39-84) 
(101) .
2.1.3 Parathyroid Hormone Related Protein
In two studies (Chapters 6,8) PTHrP was measured in plasma 
using a commercial IRMA supplied by the Nichols Institute 
(San Juan Capistrano) . A full evaluation of this assay was 
performed as a component of this thesis (Chapter 8) and has 
recently been published (102). Blood samples for this 
assay have to be collected into tubes containing protease 
inhibitors (aprotinin, leupeptin, pepstatin and EDTA). 
Sensitivity of the assay is 0.7 pmol/L (22% CV) (98) and 
the CV <10% over the range 1.5-50 pmol/L. The assay is 
highly specific and cross reactivity was <0.1% with human 
PTH (1-34) and PTH (1-84) at 10, 100 and 1000 pmol/L of PTH 
peptide.
2.1.4 Thyroid Hormones and Thyroid Stimulating Hormone 
Total thyroxine (TT4) was measured in serum by an in-house 
RIA utilising antibody supplied by the Scottish Antibody 
Production Unit (SAPU, Law Hospital, Carluke ML8 5ES). The 
assay sensitivity is 20 nmol/L (22% CV) (98) and the CV of 
the assay is <10% across the range 40-250 nmol/L.
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Total tri-iodothyronine (TT3) was measured in serum by an 
in-house RIA utilising antibody supplied by SAPU (Law 
Hospital, Carluke ML8 5ES). The assay sensitivity is 0.3 
nmol/L (22% CV) (98) and the CV <10% across the range 0.5- 
5.0 nmol/L.
Free thyroxine was measured in serum using an in-house RIA 
which uses magnetic antibody-containing microcapsules. 
Anti-thyroxine antibody for encapsulation was obtained from 
Dr T Merrit, Rast Allergy Unit, Benedin Chest Hospital, 
Kent. This assay has a detection limit of 3 pmol/L (22% 
CV) (98) and a CV of <10% over the range 8-75 pmol/L (103) .
Thyroid stimulating hormone (TSH) was measured in serum by 
an immunoflurometric assay (IFMA) (Delfia, Pharmacia Ltd., 
Milton Keynes). This assay has a detection limit of 0.05 
mlU/L (22% CV) (98) and a CV of <10% across the range 0.01- 
50 mlU/L (104) .
2.1.5 Cortisol
Cortisol was measured in extracted urine and serum using a 
direct solid-phase RIA employing 125I iodohistamine linked 
to the carboxyl derivative, 3-(o-carboxymethyl) oxime of 
cortisol (105). The between batch CV over the range 100- 
1000 nmol/L was 11% and the within batch CV 7% over the 
range 300-1500 nmol/L. Sensitivity of this assay was 20 
nmol/L as determined by the 22% CV obtained from cumulative 
precision profile data (98) .
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2.1.6 Glucagon
Measurement of glucagon was performed using a commercial 
RIA supplied by Cambridge Medical Technology (Billerica 
USA) that has a detection limit of 70 ng/L (22% CV) (98) 
and a working range of 100-4000 ng/L (<10% CV) as defined 
by the precision profile for the assay. Samples for 
glucagon assay were taken into EDTA tubes separated 
immediately and stored at -20°C prior to assay.
2.1.7 Prolactin
Prolactin was measured using an IRMA method (NETRIA, St. 
Bartholomew's Hospital, London, UK) that has a detection 
limit of 30 mU/L (22% CV) (98) and a working range of 60- 
3500 mU/L (CV <10%).
2.1.8 Routine Biochemical Analysis
Serum calcium, phosphate, creatinine, and albumin were 
measured using standard automated methods on either a 
Technicon SMAC II (Tarrytown USA) or Hitachi 704 
(Boehringer Mannheim, Lewes, UK) . Calcium was adjusted for 
albumin as described by Gardner et al (106) . Urine 
calcium, phosphate and creatinine were measured by standard 
automated methods on a Hitachi 704 (Boehringer Mannheim, 
Lewes, UK).
2.1.9 Renal Tubular Reabsorption of Phosphate
The notional threshold for renal tubular reabsorption of 
phosphate (TmP04) was determined from fasting serum and
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urine measurements using a nomogram (107). The reference 
range is 0.80-1.40 mmol/L of glomerular filtrate.
2.1.10 Urinary Calcium Excretion
Urinary excretion of calcium was expressed as a molar ratio 
relative to urine creatinine (Ca/Cr; mmol/mmol; reference 
range less than 0.70). In the fasting state Ca/Cr ratio is 
thought to be an index of net bone resorption (108).
2.2 Imaging Techniques
2.2.1 Thyroid Hormone Uptake Scan
Thyroid scans were performed using standard techniques 
following injection of 8 0 megabequerels of Technetium 
("Tern) .
2.2.2 Radionuclide Bone Scan
Radionuclide bone scans were performed using standard 
techniques three hours after the intravenous injection of 
53 0 megabequerels of "Tern labelled methylene diphosphonate.
2.2.3 Technetium/Thallium Subtraction Scan
Parathyroid localisation studies were performed using a 
scanning technique where images were acquired in 1 min 
segments for 2 0 min after the intravenous administration of 
8 0 megabequerels of 201t 1 then 10 min after 18 0 megabequerels 
of "Tern. Images were stored in a computer interfaced to 
the gamma camera and a "subtraction" scan was then obtained
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which highlighted the parathyroid adenoma (109)
2.3 Statistical Techniques
2.3.1 Cosinor Rhvthmometrv
Statistical analysis of circadian rhythm parameters was 
performed using the Cosinor technique (110). In this 
procedure, a cosine curve with a period of 24h was fitted 
to the data for each individual using the method of least 
squares. An F-statistic was then used to test the zero- 
amplitude hypothesis for a circadian rhythm. The
parameters calculated are: the mesor (rhythm adjusted
mean), the amplitude (half the total extent of the 
predictable change) and the acrophase (crest time of the 
best fit cosine function, in relation to local midnight).
2.3.2 Mann-Whitnev U Test
In studies where the data collected is not normally 
distributed and the sample sizes result in different 
variances a nonparametric statistical method of analysis 
has been applied (111) .
2.3.3 Analysis of Variance (ANOVA)
In studies where repeated t-tests or Mann-Whitney analysis 
would be inappropriate ANOVA was performed. In this 
analysis the data sets are usually greater than two and the 
distribution may or may not be normal. This analysis is 
applied in situations where multisample hypotheses are
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being tested (112)
2.3.4 Students t-Test
Comparisons of paired data within group or within subject 
where the data is normally distributed have been performed 
using the Students t-test. In all cases where this test 
has been applied the two-tailed hypotheses have been tested 
(112,113) .
2.3.5 Wilcoxon Signed Rank Test
Comparisons of paired data where the values are not from a 
normal distribution have been performed using the Wilcoxon 
signed rank test (114) .
2.3.6 Linear Regression
The functional dependence of two variables on one another 
has been analysed by simple regression analysis. Data 
suitable for this analysis consists of a dependent variable 
that is a random effect factor and an independent variable 
that is either a fixed effect or a random effect factor. 
In this analysis values are assumed to be normally 
distributed, the variances are equal, errors in X are 
minimal and Y are additive (115).
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Chapter 3
Variation in Cyclic Adenosine Monophosphate 
in Plasma and Urine During a 24 hour Period
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3.1 Variation in cAMP in Normal Male Subjects
3.1.1 Introduction
The importance of fluctuations in the secretion of hormones 
throughout a 24h time period has been increasingly
recognised during the past decade. The variations in
plasma hormone concentrations have physiological importance 
and the absence or alteration of normal rhythms can be 
pathological and may be diagnostic of certain disease 
states. Both urine and plasma cAMP concentrations reflect 
an integrated effect of several hormones on their 
receptors, as well as kidney function, making
interpretation of the cause of cyclical variations in cAMP
difficult. Several authors have demonstrated the existence 
of a circadian rhythm in UcAMP (63,116,117,118,119) with a 
remarkable consistency in timing of the excretion trough 
(0300-0900h). In contrast there has been little agreement 
on the timing of the peak excretion of UcAMP with 13 00- 
1500h (63), 0900-1200h (116), 1800-2100h (118), 0900-1200h 
(119) and a bimodal population with both 0400-0800h and 
1200-1600h (117) proposed as the period of peak UcAMP
excretion.
A circadian rhythm for cAMP in plasma has been described 
(117,120,121,122) and again whilst there is good agreement 
on the timing of the PcAMP trough (0200-0400h) major 
differences are found in the timing of the PcAMP peak 
(0800, 0600, 1200, 1400, 1600 and 2400h).
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There has been little investigation into the factors 
controlling or affecting the daily variation in cAMP. In 
addition to PTH, adrenaline and noradrenaline have been 
proposed as the main hormones affecting both plasma and 
UcAMP rhythms (118,122,123). UcAMP in females is maximal 
around the time of ovulation and minimal during menses 
(124) . There is also a significantly higher UcAMP 
excretion in women with the pre-menstrual tension syndrome 
(124). These effects are thought to be mediated by LH and 
FSH since amenorrhoea and the use of a contraceptive pill 
significantly reduced the mid cycle UcAMP excretion whilst 
decreasing UcAMP output (124). Indirect effects have been 
proposed with exercise, caffeine and smoking all implicated 
in the generation of PcAMP variations (125,126,127) . There 
is strong evidence that the circadian rhythm in PcAMP is 
the result of postural variations and orthostatism and that 
the rhythm is absent in subjects confined to bed for 32h 
(12 8) . Few studies have analysed data on both urine and 
plasma cAMP concentrations simultaneously and surprisingly 
there has been no attempt to study the role of the major 
cAMP controlling hormones PTH and glucagon in generating 
cAMP 24h rhythms. This probably reflects the previous 
difficulties experienced in measuring accurately both these 
hormones.
Improvements in immunoassay techniques in recent years have 
led to the development of immunometric assays for the 
intact molecule of PTH, PTH (1-84), which are specific and
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sensitive and are able to measure PTH (1-84) in all normal 
subjects with a concentration well above the detection 
limit of the assay (100,101,129). These assays overcome 
the problems of circulating fragments of PTH interfering in 
the measurement of PTH (1-84) and enable physiological 
studies to be performed.
An understanding of the factors responsible for glucagon 
degradation and improved antibody technology targeted at 
the correct portion of the glucagon molecule has meant that 
glucagon measurements can now be made in normal subjects 
and physiological studies performed with confidence.
3.1.2 Subjects and Methods
In all the 24h studies described in this chapter a standard 
blood and urine sampling technique was adopted. Subjects 
were admitted to a hospital ward between the hours 1000- 
1200. A venflon cannula was placed in a vein in the median 
cubital fossa for blood sampling and urine was collected 
into a volumetric flask at 4h intervals during the day and 
one sample obtained immediately on rising from sleep 
corresponding to an overnight sample. The studies were 
performed over the period 1400-133Oh and the maximum number 
of subjects sampled at one time was 6 with the usual number 
being 3. All subjects ate at the same times when studied 
and a standard diet was consumed during each study period, 
although no run in period of standard diet was given. All 
subjects were ambulant but avoided exercise and lay down to
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sleep and arose from bed at the same time.
In the initial study six healthy male volunteers (age 29- 
40; mean 3 3 years) were studied over a 24h period. None of 
these males were suffering from any illness or taking 
medication known to interfere with calcium metabolism. The 
subjects were ambulant but avoided exercise during the 
study period. They lay down to sleep at 010 Oh, were 
awakened at 0700h arising at 0800h.
All samples obtained from an individual subject were 
analysed in the same assay batch.
The sample type for each analysis has been described in 
Chapter 2. Each serum or plasma was obtained within 3 0 min 
of venesection and immediately frozen and stored at -70°C 
or -2 0°C/ depending on the analyte being measured, prior to 
analysis. In this study PTH (1-84), UcAMP, NcAMP, 
glucagon, calcium, phosphate, creatinine and albumin were 
measured. All measurements were performed as specified in 
Chapter 2.
3.1.3 Results
The mean 24h profiles of PTH (1-84), NcAMP, glucagon and 
PcAMP in the six subjects are shown in Figure 2. PTH (1- 
84) rises from 013Oh in a broad peak through the night and 
early morning. The concentrations from 0200 to 0600h were 
significantly elevated (pcO.001) compared to baseline
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24 h profiles of PTH(l-84), NcAMP, Glucagon and 
PcAMP in 6 normal males. Results are mean ± SEM.
(1400-1800h). The PTH (1-84) concentrations in all 
subjects returned to baseline values by lOOOh although the 
rate of fall varied markedly between individuals. The mean 
intra-individual CV between 063 0 and lOOOh was 3 0% (range 
12.9-42.5) compared to 17% (12.6-23.6) in the basal period.
Mean NcAMP concentrations rose throughout the night and 
early morning in parallel to the PTH (1-84) . The mean NcAMP 
concentrations at eight of the eleven time points during 
the period 0200 to 0700h were significantly elevated 
(p<0.01) compared to the baseline means (1400-1800h).
Plasma cAMP fluctuates considerably during the 24h period 
and there is wide individual variation. A significant 
(p<0.01) concerted decrease in PcAMP occurs during the 
night and early morning with eleven of the twelve time 
points from 0200-0700h lower than baseline (1400-1800 h) . 
A significant decrease (p<0.01) in PcAMP was observed in 
the post-prandial period from 1800-2100h. The most 
significant increase in PcAMP was noted when all subjects 
rose from their beds in the morning peaking lh after moving 
from recumbency to standing. PcAMP decreased following 
breakfast from the peak at 0800h to a nadir at lOOOh then 
gradually increased over the remaining study period. PcAMP 
decreased significantly following each meal time (1800, 
2300, 0800 and 1300h) (p<0.05).
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Glucagon decreased significantly (p<0.05) during the night 
and early morning in parallel to PcAMP with all twelve time 
points from 0200-0700h significantly lower than baseline 
(1400-1800) . The changes in glucagon showed less 
fluctuation than PcAMP but similar decreases in glucagon 
were observed following each meal time.
Cosinor analysis of the data was performed Table 2 and 
indicated a tight phase and frequency synchronisation in 
the PTH(1-84) and glucagon concentrations of the six 
subjects over the 24h period. The results confirm a 
significant circadian rhythm in PTH (1-84) and glucagon but 
although there is phase synchrony in the NcAMP 
concentrations variability in amplitude is such that the 
mean amplitude of 5.9 from the mesor concentration of 25 
nmol/L GF is not statistically significant at the 5% level. 
Variability in the PcAMP data is such that no statistically 
significant circadian rhythm is demonstrated.
3.1.4 Discussion
Both serum PTH (1-84) and NcAMP concentrations increase 
significantly during the night and early morning, with mean 
values above the day-time reference ranges for these 
analytes. The cosinor analysis confirms significant 
circadian rhythm in PTH (1-84) , with an acrophase at 0405h. 
This is consistent with the night-time rise in 
immunoreactive PTH previously reported using C-terminal 
specific assays (130,131) and also with the hypothesis that
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Acrophase Mesor Amplitude Significance
24 h clock
PTH 1-84 0405 3.3
pmol/L
0.7
pmol/L
P<0.05
NcAMP 0524 25.0 
nmol/L GF
5. 9 
nmol/L GF
NS
Glucagon 1759 305.0
ng/L
36.8
ng/L
P<0.01
PcAMP 1443 18.2
nmol/L
1.2
nmol/L
NS
NS - Not Significant
Table 2 Cosinor analysis of 24 h profiles of normal males
the rise may be sleep related (132)
These results show that the circadian variations in PTH (1- 
84) are accompanied by parallel variations in NcAMP levels. 
This supports the conclusion that the PTH (1-84) released 
through the night is physiologically active at the kidney. 
The kidney has not been exposed to an increased filtered 
load of cAMP as PcAMP fell overnight and so the results 
explain why measurements of total urinary cAMP failed to 
correlate with proposed PTH effects and circadian rhythm in 
the past. The close correlation between NcAMP and PTH 
which is independent of PcAMP supports the use of NcAMP as 
a marker of end organ PTH activity.
Although the NcAMP concentrations increased significantly, 
the cosinor analysis failed to detect a significant phase 
and frequency synchronised rhythm for the six subjects. 
This is probably related to the number of subjects studied 
and the inherent variability in this measurement which is 
calculated from four separate analyses.
NcAMP concentration remained elevated (0600-0700h) after 
the main peak of PTH (1-84) . This is partly due to the 
study design as urine was collected on rising in the 
morning after sleep and so the NcAMP calculations overnight 
will be a reflection of the changes in PcAMP at each time 
point over an integrated urine collection for each subject. 
However, studies using catheterised animals or human
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subjects (46) have indicated that total UcAMP decreases by 
a minimal amount then remains constant overnight and so the 
calculated NcAMP will be a good estimate of true NcAMP 
production at each time point.
Plasma glucagon and cAMP decrease significantly overnight 
and glucagon demonstrates a significant circadian rhythm. 
The overall pattern of glucagon and cAMP secretion over 24h 
is very similar and a strong correlation exists between the 
two analytes over the 24h period. It is known that 
glucagon stimulates cAMP production from liver and from 
this current data glucagon would appear to be making a 
major contribution to the circulating PcAMP. A 50% 
decrease in glucagon overnight is accompanied by a 50% 
decrease in PcAMP and the role of glucagon in the 
generation of PcAMP is further supported by the transient 
falls in both analytes following mealtimes. These data 
would indicate that PcAMP in the physiological situation is 
influenced more by glucagon than PTH. Although PcAMP in 
pharmacological studies can be used to rapidly monitor PTH 
action (55,85) in physiological and pathophysiological 
studies NcAMP is a more reliable index of PTH activity.
Significant fluctuations exist in PcAMP on top of the 
inherent circadian rhythm which make the cosinor analysis 
difficult to apply and inappropriate for this data. PcAMP 
reflects the integrated effect of several hormones and it 
is likely that other hormones, particularly the
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catecholamines, are affecting the values obtained. A 
transient fall in catecholamines occurs on recumbency and 
sleep with a significant increase on rising early in the 
morning and these hormone changes will also contribute to 
the overall appearance of the PcAMP profile. Several other 
hormones act through cAMP and in disease states, or in 
altered physiology, the effects of one or other of these 
hormones may predominate altering cAMP metabolism.
The existence of a circadian rhythm in PTH (1-84) which is 
physiologically active raises a number of questions related 
to the control of PTH (1-84) release and its effects on 
cAMP metabolism. In subsequent chapters studies have been 
performed to analyse cAMP metabolism during health, under 
physiological manipulation and in disease during 24h 
periods and at selected single time points.
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3.2 Sleep Shift Effects on cAMP Metabolism, PTH(1-84),
Glucagon and Prolactin in Normal Male Subjects
3.2.1 Introduction
The mechanism controlling the nighttime rise in PTH (1-84) 
and NcAMP is not yet known. It has been concluded from a 
number of studies (130,132,133,134,135,136,137) that the 
PTH (1-84) rhythm cannot be accounted for solely by changes 
in serum calcium or phosphate concentrations and therefore 
the central nervous system may play a role either directly 
or indirectly in modulating normal PTH (1-84) secretion. 
Prolactin (PRL) secretion follows a similar pattern to PTH 
(1-84) over a 24h period in normal male subjects with an 
early evening rise and a major night-time elevation 
occurring shortly after the onset of sleep (138,139) . 
Cross-correlation analysis of 24h profiles confirmed a 
strong temporal correlation between PTH (1-84) and PRL 
secretion in normal male subjects with the changes in PRL 
secretion occurring approximately 2h after those in PTH (1- 
84) (136) . It has been postulated therefore that there may
be neuroendocrine control common to PTH (1-84) and PRL 
secretion which would subsequently affect cAMP production.
The overall circadian characteristics (excluding food 
intake or dietary effects) of a 24h hormonal profile 
generally represent an integration of the effects of 
circadian rhythmicity (intrinsic effects of time of day 
irrespective of the sleep or waking state), sleep
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(intrinsic effects of sleep irrespective of time of day) , 
and pulsatile secretion occurring at frequencies of minutes 
or hours. To delineate the relative roles of circadian and 
sleep effects, strategies based on the fact that circadian 
rhythmicity needs several days to adapt to abrupt shifts of 
the sleep-wake cycle have been employed. Thus, by shifting 
the sleep times by 7-12h, any masking effects of sleep on 
circadian inputs are removed and the effects of sleep at an 
abnormal circadian time can be revealed. In this study a 
sleep-shift experiment was performed in which the time of 
sleep was delayed by 7h in six normal male subjects.
3.2.2 Subjects and Methods
The six normal healthy male subjects from the previous 
study were sampled exactly one year following the original 
study thus avoiding the possible effects of seasonal 
changes in calcitropic hormones. Study A (circadian) was 
described in Chapter 3.1. In study B (sleep shift) the 
subjects were awake from 1400-0800h and slept from 0800- 
1400h. All subjects ate identical meals in both studies 
(at 1800, 2300, 0800 and 1300h in study A and 1800, 2300,
073 0 and 143 0 in study B) . Timed urine samples were 
obtained 4 hourly when awake and one sample obtained after 
awaking from sleep.
All analytes studied in Chapter 3.1 were measured and in 
addition serum prolactin (PRL) was measured in this study. 
Methods of analysis were as outlined in Chapter 2 and NcAMP
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was calculated by the method of Broadus et al (46) . 
Statistical analysis was performed using a paired t-test to 
compare results within an individual and the Mann-Whitney 
U test between studies.
3.2.3 Results
The mean (± SEM) PTH (1-84), NcAMP are shown Figure 3, 
PcAMP, glucagon Figure 4 and PRL Figure 5 in each of the 
studies. Overall mean 24h concentrations, the range of 
values and the coefficient of variation for PTH (1-84) , 
NcAMP, PcAMP, PRL, glucagon and adjusted calcium in each of 
the six subjects for the circadian and sleep-shift studies 
are shown in Tables 3a and 3b.
A comparison of the profiles has been made Figure 6 (PTH 
(1-84), NcAMP, PRL and adjusted Ca) and Figure 7 (P-cAMP 
and glucagon) which highlights the trends during the hours 
of sleep by smoothing the profiles using a three-sample 
moving average technique to minimise the perturbations due 
to either pulsatile secretion or assay noise and the error 
bars omitted for clarity.
Comparison of the profiles of each analyte indicates that 
sleep shift has altered the pattern of both secretion of 
the hormones studied and cAMP. The nocturnal rise in PTH 
(1-84) is present in both studies despite the shift in the 
sleep-wake cycle. However, the start of the sleep wake 
cycle is attenuated by sleep delay with the PTH
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Figure 7 Smoothed (3 point moving average) mean 24h 
profiles for PcAMP and glucagon under normal 
(circadian) and sleep shift conditions in 6 
normal males.
concentrations in each individual significantly lower in 
the sleep-shift study from 0200-0300h (p<0.05). NcAMP
rises overnight in both studies but the rise during the 
sleep-shift experiment is markedly reduced with mean NcAMP 
from 0130-0700h calculated to be 23.8 nmol/L GF compared to 
31.9 (p<0.01) in the circadian study. In the circadian
study an early morning peak in PRL is seen which is absent 
in the sleep-shift study. However, an increase in PRL
occurs coincident with the time of delayed sleep in the 
sleep-shift study. Initial comparisons of the PcAMP 
profiles are very similar and a decrease in PcAMP from 
0130-0230h is seen in both studies. After 0230h the two 
profiles differ markedly with peaks and troughs occurring 
at different times in each study and a concerted decrease 
in PcAMP coincident with the time of delayed sleep in the 
sleep-shift experiment. The profile of glucagon excretion 
is also very similar in the early part of the studies. A 
significant difference in excretion exists at two time
periods coincident with sleep in both studies with glucagon 
significantly lower (p<0.01) when asleep compared to basal 
secretion in the same study or the equivalent time period 
between the studies (p<0.05).
3.2.4 Discussion
Early studies using this type of experimental design
demonstrated that the secretion of some hormones, such as 
cortisol (140) and melatonin (141), is primarily modulated 
by circadian rhythmicity, whereas others such as PRL
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(13 8,142) and growth hormone (143) are strictly sleep 
dependent. The shift in the timing of the PRL peak seen in 
this acute sleep-shift experiment is consistent with early 
studies on PRL secretion which had shown that daytime naps 
are associated with increases in PRL (142) and that acute 
reversal or delay of the sleep wake cycle is accompanied by 
an increase in PRL during daytime sleep (13 8). However, 
more recent studies on repeated sleep shifts as part of a 
jet lag study have shown a splitting of the PRL peak 
revealing an endogenous circadian component to PRL 
secretion in addition to the sleep-related component (13 9) . 
It is now accepted that sleep effects and circadian effects 
interact to produce the overall temporal pattern of the 
majority of hormones and that different portions of the 
wave shape of the hormonal pattern adapt at different rates 
to manipulations of the sleep wake cycle.
In this acute sleep-shift experiment the overall timing of 
the main nocturnal PTH (1-84) rise did not alter 
substantially from the normal circadian pattern. Thus the 
data on PTH (1-84) secretion from this experiment is 
consistent with a primary circadian rhythm, i.e. 
intrinsically linked to the time of day. However, 
nocturnal PTH concentrations have been shown previously to 
be temporally correlated with cycles of stage 3 and 4 sleep 
(132) and this may be reflected in this study by the early 
part of the peak being blunted with a significant decrease 
in PTH (1-84) from 0200-0300h. These data are consistent
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with the postulate that the control of PTH (1-84) secretion 
is primarily circadian but may be modified by sleep. 
Another example of this type of control is that of TSH 
which is primarily circadian but suppressed by sleep such 
that in sleep deprivation experiments the evening rise in 
TSH is enhanced and prolonged (144).
Comparison of the NcAMP profiles between the two studies 
indicates a markedly attenuated nocturnal NcAMP output in 
the sleep-shift experiment. These results suggest that the 
end organ response, the nocturnal production of NcAMP at 
the kidney, may not solely be determined by PTH (1-84) but 
is modified by other factor(s). For example cortisol (145, 
14 6 and Chapter 5), T4 (147, 148 and Chapter 4), T3 (149)
and insulin (150) can modify the cAMP response evoked to 
PTH in cell systems and in humans. In particular cortisol 
and thyroid hormones can alter the threshold concentration 
at which PTH can produce a cAMP response (145,146,148,149) . 
Although such effects have largely been shown to occur at 
supraphysiological concentrations and in- vitro, it is 
conceivable that under normal circumstances the increase in 
NcAMP during the night is likely to be the result of a 
concerted effect of a number of hormones acting to 
facilitate PTH stimulation of cAMP. This phenomenon may be 
disrupted by an acute sleep shift.
It can be seen that a significant change in the profile of 
PcAMP has taken place which only in part reflects the
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alteration in glucagon secretion. The nadir of secretion 
corresponds to sleep and recumbency in both studies at the 
time when glucagon concentrations are at their lowest. In 
the sleep-shift experiment, however, a decrease in PcAMP is 
observed at a time when mean glucagon concentrations are 
rising and considerable fluctuations are observed in PcAMP 
over the period 0130-0700h which probably reflect the 
disturbed balance between hormones that are entrained to 
the biological clock and those that are entrained to the 
time of day.
There is evidence to link PRL to PTH and calcium metabolism 
(151,152,153). The recent finding that PRL can stimulate 
PTHrP release into breast milk and influence PTHrP 
messenger RNA expression adds weight to the association of 
PRL and calcium metabolism (154) . It is interesting to 
speculate whether the night-time rise in NcAMP during the 
normal sleep wake cycle has a PRL-dependant, and therefore 
sleep-dependent, component perhaps related to the 
production of PTHrP rather than PTH (1-84).
Thus, although the results of this acute sleep-shift 
experiment argue against a direct neuroendocrine link 
between PTH (1-84) and PRL secretion, the circadian 
studies, performed to date, demonstrate that these hormones 
are maintained by the circadian clock in a distinct phase 
relationship throughout a 24h period in normal subjects. 
The changes observed in cAMP metabolism, particularly
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NcAMP, in this study reflect the alteration of activity of 
several hormones and it may be that a high degree of 
temporal organisation allows concerted metabolic effects 
between PTH and other hormones leading to optimised end 
organ responses.
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3.3 The Effect of a 96 Hour Fast on cAMP Metabolism, PTH 
(1-84) and Glucagon in Normal Male Subjects
3.3.1 Introduction
PTH (1-84) secretion and NcAMP production in normal males 
follows a defined circadian rhythm (137,155, Chapter 3.1). 
Evidence for neuroendocrine control arises from the 
observation of a strong temporal correlation between PTH 
(1-84) and PRL (13 6). The sleep shift experiment (Chapter
3.2) argues against a direct neuroendocrine link between 
PRL and PTH (1-84) indicating that the PTH (1-84) and NcAMP 
rhythms are mainly circadian in nature, that is 
intrinsically linked to the time of day with the 
possibility of modification by the presence of sleep.
Throughout the studies on the circadian secretion of PTH 
(1-84) the most striking and consistent relationship found 
has been between PTH (1-84) and serum P04. From evidence in 
the literature it has been concluded that this relationship 
reflects the influence of PTH on the renal handling of 
phosphate with this action mediated via cAMP. The 
strongest evidence against a direct role for phosphate in 
the control of the circadian rhythm of PTH secretion is 
that of Jubiz et al (13 0) who reported that following a 
fast the PTH circadian rhythm persisted while that of 
phosphate was abolished.
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It should be noted that this key study on the inter­
relationship between phosphate and PTH secretion was 
performed some twenty years ago. Since that time the 
highly specific two-site immunometric assays have been
developed which allow the measurement of subtle changes in
PTH (1-84) concentrations and have permitted improved 
definition of the physiology and pathophysiology of PTH (1- 
84) secretion (156).
In the following study the effects of fasting on the 24h 
rhythms of PTH (1-84), NcAMP, PcAMP, glucagon, serum 
adjusted Ca and serum P04 have been investigated.
3.3.2 Subjects and Methods
Six normal male volunteers (age 28-40, mean 32 years) were 
studied on two separate occasions. During one study
(Control) on the day of sampling the subjects ate identical 
meals at defined times (1800, 2230, 0800 and 1200h), were
ambulant but avoided exercise and lay down to sleep at an 
identical time (0100-0700h). For the other study (Fasting) 
the subjects consumed no food but were allowed water ad 
libitum for 96h and were sampled during the final 24h of 
the fast. The subjects followed an exercise and sleep
regime identical to that of the control study. Three 
subjects were randomised to the control study followed by 
the fasting study whilst the other three subjects fasted 
first then subsequently took part in the control study. A 
minimum of three months separated each study period. Blood
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and urine samples, for the measurements described in 
Chapter 3.1, were obtained, stored and assayed as described 
Chapter 2.
Statistical analysis was performed using the paired 
difference t-test to analyse significant changes within 24h 
profiles. Mann Whitney U comparisons were used to analyse 
differences between study periods. Cosinor techniques were 
used to analyse circadian rhythm parameters.
3.3.3 Results
The 24h profiles for serum P04, adjusted calcium, PTH (1-84) 
and NcAMP are shown in Figures 8 and 9. Comparisons of the 
profiles of PcAMP and glucagon are given Figure 10.
Results from the control study are shown above the
corresponding results from the fasting study figures. The 
results of the cosinor analysis of the data contained in 
the figures are summarised in Table 4. As anticipated, the 
process of fasting for 96h effected a dramatic change in 
the 24h pattern of serum P04. In the control study there 
was a pronounced circadian rhythm of P04 which is highly 
significant when analysed by cosinor analysis. In the 
fasting study the nocturnal peak of phosphate was almost 
completely abolished and cosinor analysis confirms the
absence of any significant circadian rhythm. It is worthy 
of note that for most of the 24h period serum P04
concentrations were higher in the control study (mean 1.20 
mmol/L) than in the fasting study (mean 1.13 mmol/L,
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Figure 9 24 h profiles of PTH(1-84) and NcAMP during
normal diet and after a 96 h fast in 6 normal
male subjects. Results are mean ± SEM.
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Figure 10 24 h profiles of PcAMP and Glucagon during
normal diet and after a 96 h fast in 6 normal
male subjects. Results are mean ± SEM.
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Table 4 Cosinor analysis of 24h profiles of serum P01,
adjusted Ca, NcAMP, PTH (1-84), PcAMP and glucagon 
whilst consuming normal diet and following a
96h fast
p<0.01)
The 24h mean of serum adjusted Ca concentration was also 
higher in the control study (2.40 mmol/L) than in the 
fasting study (2.26 mmol/L, p<0.01) but the pattern 
throughout the day did not differ markedly between studies. 
Cosinor analysis did not detect a synchronised circadian 
rhythm in serum adjusted calcium concentration in either 
study. Using the group mean concentrations over the 
initial period of the study as baseline (1400-1800h) a 
statistically significant transient decrease in adjusted 
calcium was observed in the control study during the sleep 
period (2.44 to 2.40 mmol/L at 0130h; p<0.05) . No
corresponding decrease in adjusted calcium was detected in 
the fasting study. The mean adjusted calcium was lower at 
the end of both studies than at the beginning and may in 
part reflect daily variation. This was also a consequence 
of greater individual variability in the latter part of the 
study.
Figure 9 reveals a marked alteration in the pattern of PTH 
(1-84) concentrations over the 24h period as a result of 
fasting, despite similar 24h mean concentrations (control
3.3 pmol/L; fasting 3.5 pmol/L). The nocturnal rise seen 
in the control study is absent in the fasting profile with 
PTH (1-84) concentrations decreasing during the night and 
early morning when fasting. In the fasting study the mean 
PTH (1-84) concentrations were significantly lower during
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the time of sleep (fasting 2.8 pmol/L; control 3.5 pmol/L; 
p<0.01) but higher during waking hours (fasting 3.1 pmol/L; 
control 2.4 pmol/L; p<0.001). Figure 9 also reveals that 
the between subject variability was greater in the fasting 
study than in the control study. Cosinor analysis of the 
PTH (1-84) profiles indicates a significant circadian 
rhythm in the control study but fails to detect a 
synchronised rhythm in the fasting study.
NcAMP results are very similar in pattern to those of PTH 
(1-84) . Thus the nocturnal peak of NcAMP coincident with 
that of PTH (1-84) in the control study was absent 
following fasting. Of major importance was the significant 
decrease in mean NcAMP following fasting (control 25.0 
nmol/L GF; fasting 11.6 nmol/L GF; p<0.001). This 
difference is in part due to the absence of the nocturnal 
rise in NcAMP but is also due to a significant decrease in 
mean NcAMP during the waking hours 0800-0100 (control 22.1 
nmol/L GF; fasting 12.1 nmol/L GF p<0.001). Although an 
increased variability in PTH (1-84) is observed when 
fasting the variability in NcAMP production is reduced.
PcAMP is significantly higher (p<0.01) following fasting 
when compared to the control and the profile over 24h 
altered so that a gradual decrease in PcAMP was noted from 
2100-0600h with a less pulsatile pattern of secretion 
observed when compared to control. Glucagon concentrations 
are also significantly higher (p<0.01) after fasting with
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little variation in concentration over the 24h and in 
particular the post prandial decreases noted in the control 
study are absent during fasting and the sleep/orthostatism 
related decrease is not so obvious during fasting. These 
alterations in glucagon and PcAMP secretion abolish the 
glucagon circadian rhythm but result in a significant PcAMP 
rhythm following the fast.
3.3.4 Discussion
The 96h fast incorporated into this study resulted in the 
loss of the 24h rhythm of serum P04 from a group of normal 
adult male subjects. This result, together with the 
accompanying reduction in the mean 24h serum adjusted 
calcium concentration, is consistent with the findings of 
other fasting studies (157,158). Of major significance, 
however, is that unlike the one previous study in which it 
was examined (13 0) the current study has demonstrated that 
a 96h fast results in attenuation of the normal circadian 
rhythm of both PTH (1-84) and NcAMP with a significant 
reduction in NcAMP production following this fast.
There are four main possible explanations for the 
difference between the results of the present study and 
that of Jubiz and his colleagues in 1972 (130). Firstly,
there were more subjects in the current study (six versus 
two) . Secondly, the current study employed an increased 
sampling frequency (3 0 min versus 2h) . Thirdly, the period 
of fast was longer (96h versus 48h) . Finally, improvements
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in immunoassay in the current study meant that only the 
intact PTH molecule was measured without interference from 
fragments of the PTH molecule, with a sensitivity and 
precision capable of distinguishing small changes in PTH 
(1-84) concentration within the reference range for normal 
subjects (100,156). This combination of improved study 
design and methodology contribute to the differences in 
outcome but the possibility also exists that there is a 
gradual loss in the nocturnal surge in PTH (1-84) with an 
increasing length of fast.
The present study provides insights into our understanding 
of the chemical modulation of the circadian rhythm of PTH 
(1-84) and NcAMP. Although the higher setting of serum PTH 
(1-84) during the waking hours of the fasting study is 
probably a consequence of the reduction in the mean 
adjusted calcium concentration, the relative fall in PTH 
(1-84) during the period of sleep when fasting cannot be 
explained by changes in calcium status. These results are 
in accordance with the view that factors other than calcium 
contribute to the circadian rhythm of PTH (1-84) in normal 
subjects (130,132,133,159, Chapters 3.1, 3.2 and 3.4).
Data from the previous key study (13 0) sustained the view 
that the P04 rhythm must be a consequence of the PTH (1-84) 
rhythm. The present study results suggest that the 
converse argument is at least as valid as the serum P04 rise 
occurs before the nocturnal PTH rise. Thus the role of 
phosphate as a PTH secretagogue in normal physiology must
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be considered.
While the circadian rhythm of PTH (1-84) is lost on fasting 
the between and within subject variability of PTH (1-84) 
concentrations is increased. It is not possible with the 
sampling frequency used in this study (3 0 min intervals) to 
analyse directly the pulsatility of PTH (1-84) secretion 
since PTH (1-84) has a half life of 2-3 min. However, it 
is possible that the increase in variability observed 
represents alterations in the pulsatile nature of PTH (1- 
84) secretion. The increased variability in secretion of 
PTH (1-84) and the loss of the nocturnal rise may represent 
an adaptation to the fasting state which facilitates the 
mobilisation of calcium from bone. It has been calculated 
that approximately half the quantities of calcium and
phosphate excreted in urine during a prolonged fast have 
been mobilised from bone (158).
The changes in signal mode for PTH (1-84) observed in this
current study may offer a means of mediating bone
resorption in normal and pathological states. It is known 
that trabecular bone formation may be stimulated by 
transient rises in serum PTH following daily injection
(160) but that continuous infusions of PTH are ineffective 
or counterproductive (161). This knowledge has led to the 
postulate that the circadian rhythm of PTH (1-84), 
particularly the nocturnal rise then fall, is an essential 
element in the process of bone formation. Conversely,
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abnormalities in the rhythm of PTH (1-84) secretion as seen 
in this current study and in hyperparathyroidism (Chapter 
3.4) may lead to an alteration in the normal pattern of 
bone turnover and may contribute to the aetiology of bone 
disease including osteoporosis.
NcAMP production has been significantly altered following 
fasting and probably reflects the combined effects of loss 
of the PTH (1-84) circadian rhythm and the increased 
variability of PTH (1-84) secretion. Added to these 
changes are alterations in the mean circulating calcium, 
phosphate and possibly vitamin D which will have effects on 
the PTH receptor at the kidney. The overall result is that 
the kidney response to PTH (1-84) in terms of cAMP 
production, is significantly decreased following a fast.
As expected, mean glucagon concentrations following the 
fast are significantly elevated with no significant 
concerted decrease overnight observed although a transient 
decrease is observed between 2130 and 0230. The overall 
increase in glucagon reflects the alterations in glucagon 
metabolism that take place following a fast. It has been 
demonstrated that fasting for 3 days results in a 
significant increase in plasma glucagon as a result of 
decreased catabolism by the kidney rather than increased 
secretion by the pancreas (162). PcAMP is also increased 
over the 24h period with the development of a significant 
circadian rhythm and the retention of the nocturnal
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decrease in PcAMP. Part of the increase in PcAMP will be 
due to the rise in glucagon but the overall increase in 
PcAMP will also be due to contributions of other hormone 
effects not measured in this study. Prolonged fasting will 
result in increases of GH, PRL and cortisol which will all 
contribute to the increased PcAMP. It is also possible 
that PTH (1-84) effects are different on bone and kidney 
resulting in increased contribution to PcAMP from bone 
cells but a decreased contribution from the kidney. These 
effects may be due to the acute ketosis that exists 
following a fast as altered PTH responses in acute acidosis 
have been observed in the kidney and bone. An increase in 
cAMP production by isolated perfused dog bone has been 
reported in acidosis (163) whilst decreased UcAMP excretion 
has been found in rats or dogs made acidotic (164,165) .
This study has shown that a prolonged fast can markedly 
alter phosphate, calcium, PTH (1-84), NcAMP and glucagon 
rhythms. The results suggest that phosphate may play an 
important role in the genesis of the PTH (1-84) rhythm and 
subsequent NcAMP rhythm. Further work is required to 
investigate such mechanisms and the role other circadian 
hormones may play, such as GH and cortisol, in regulating 
calcium and phosphate homeostasis and the action of PTH (1- 
84) in generating cAMP.
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3.4 Variation in The Circadian Rhythm of cAMP in
Hvperparathyroid Patients Before and After 
Parathyroidectomy
3.4.1 Introduction
The demonstration of the significant elevation of NcAMP 
rising in parallel with PTH (1-84) in normal males (Chapter 
3.1) and the ability to modify these profiles by 
manipulating sleep (Chapter 3.2) and diet (Chapter 3.3) 
raises questions about the role of these rhythms, if any, 
in health and disease. Patients with primary
hyperparathyroidism (1°HPT) have inappropriately detectable 
or high serum concentrations of PTH (1-84) in the presence 
of hypercalcaemia (101,166,167) and an elevated NcAMP in 
the majority of cases (46,69,70). Some of the available 
evidence indicates that in 1°HPT the adenomatous 
parathyroid tissue functions autonomously, whilst other 
evidence suggests that the gland is not totally autonomous 
and an alteration in the set-point for PTH secretion 
exists. Thus we would expect that the circadian rhythm 
observed in normal subjects could be lost in 1°HPT. 
Studies measuring N and C terminal PTH have shown either 
the existence (131,159) or absence (168,130) of a circadian 
rhythm for PTH in primary hyperparathyroidism. If the 
circadian rhythms for PTH (1-84) and NcAMP are lost in 
1 °HPT then following removal of the adenoma there may be 
restoration or alteration of these circadian rhythms. In 
this study the data obtained from normal volunteers
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(Chapter 3.1) and 2 additional subjects has been compared 
to that obtained in patients with 1°HPT before and after 
surgical removal of a parathyroid adenoma.
3.4.2 Subjects and Methods
An additional two normal male volunteers (aged 38 and 43) 
were sampled at the same time as the hyperparathyroid 
patients giving a total of eight normal healthy males (six 
of these as described in Chapter 3.1) and eight patients 
with 1°HPT studied. The patients with 1°HPT (age 32-79, 
mean 52 years, 4 male, 4 female) were all hypercalcaemic 
(serum adjusted Ca >2.6 mmol/L) with detectable or elevated 
PTH(1-84) (4.8-68.0 pmol/L) on more than one occasion and
parathyroid adenomas were detected by technetium/thallium 
subtraction scan in all cases. Six 1°HPT patients had 
parathyroid adenomas (histological confirmation) removed 
surgically after neck exploration. Following operation all 
six patients became normocalcaemic and PTH(1-84) 
concentrations normalised. Patients with 1°HPT were 
sampled over a 24h period on two occasions, 1) at least 2 
months prior to surgery and, 2) at least 6 months following 
surgery. During the study periods the patients were 
hospitalised, they ate hospital diet at identical times, 
were ambulant but avoided exercise and all lay down to 
sleep at an identical time (2300h). The standard sampling 
protocol was followed as described previously.
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PTH (1-84) , NcAMP and PcAMP values showed a wide scatter in 
patients with 1°HPT so, for clarity, the results were 
calculated for each subject as percentage difference from 
their 24h mean value. Statistical analysis was performed 
using paired difference t-test to analyse significant 
changes within 24h profiles. Mann-Whitney U-test was used 
to analyse differences between groups. Circadian rhythm 
parameters were calculated using the cosinor technique.
3.4.3 Results
Figures 11, 12, 13, 14 and 15 show the 24h profiles for PTH
(1-84), NcAMP, (each expressed as percentage of the
individual 24h mean), PcAMP, adjusted serum Ca and serum P04 
for normal subjects, 1°HPT patients pre and post surgery 
respectively. The PTH (1-84) and NcAMP values throughout 
the 24h periods in the three groups are summarised in Table 
5. Cosinor analysis of the data for the five measurements 
in each group studied are shown Table 6.
In comparison to the normal subjects the circadian rhythm 
in both PTH (1-84) and NcAMP is lost completely in patients 
with 1°HPT with no synchronised rise in PTH (1-84) or NcAMP 
observed at any time during the 24h in these patients.
In normal subjects the greatest variability in PTH (1-84) 
occurs between 0630-1000h. In patients with 1°HPT,
concentrations of PTH (1-84) occasionally fell within the 
reference range during the 24h period and these results 
coincided with normal values for adjusted Ca. In two
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Figure 11 PTH (1-84) in normals, and 1°HPT patients pre
and post parathyroidectomy. Results are
expressed as % of 24 h mean ± SEM of each value.
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Figure 12 NcAMP in normals, and 1°HPT patients pre and
post parathyroidectomy. Results are expressed
as % of 24 h mean ± SEM of each value.
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patients with 1°HPT values for NcAMP within the reference 
range were obtained intermittently throughout the 24h. 
PcAMP was significantly higher in 1°HPT patients throughout 
the 24h (p<0.001). There was no synchronised rhythm
present in 1°HPT and no prolonged trough in PcAMP overnight 
although a decrease in PcAMP was observed on recumbency and 
an increase on rising from sleep in the morning. Following 
surgery PcAMP varied in a similar manner to the normal 
subjects with the lowest PcAMP concentrations observed 
early morning. Variability in PcAMP was greater in 
patients with 1°HPT. Analysis of the data in 1°HPT 
patients indicates that there may be 6 regular peaks of 
PcAMP in a 24h period if a simple peak counting analysis 
technique is applied to the data. A similar but less 
obvious set of peaks can also be recognised in the normal 
subjects. It is not immediately obvious from this data 
what is stimulating this pattern of secretion and why these 
peaks are bigger in 1°HPT.
Adjusted calcium varied very little during the 24h in both 
groups. A transient, statistically significant decrease 
(p<0.05) in mean adjusted calcium from 2.44 to 2.40 mmol/L 
at 0130h in normals, and from 2.94 to 2.84 mmol/L at 
midnight in patients with 1°HPT was observed when compared 
with the group mean concentration between 1400-18 0Oh. The 
adjusted calcium mean concentration in the patient group 
was predictably higher pre treatment (p<0.001) and was also 
significantly lower post treatment (pcO.OOl) than in the
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Figure 13 PcAMP in normals, and 1°HPT patients pre and
post parathyroidectomy. Results are expressed
as mean ± SEM.
Mean 
Adj Ca 
mmol/L
2.61
Normal Males
2 . 4 -
2.2
2 1 3 0  0 1 3 0  0 5 3 0  0 9 3 0  1 3 3 0
3.4 -i
Pre Surgery
3 . 0 -
2.8 -
2.6 -
2.4
1 3 3 0  1 7 3 0  2 1 3 0  0 1 3 0  0 5 3 0  0 9 3 0  1 3 3 0
2 .6  “I
Post Surgery
2 . 4 -
2 . 3 -
2.2
1 3 3 0  1 7 3 0  2 1 3 0  0 1 3 0  0 5 3 0  0 9 3 0  1 3 3 0
Time 24h Clock
Figure 14 Adjusted calcium in normals, and 1°HPT patients
pre and post parathyroidectomy. Results are
expressed as mean ± SEM.
normal subject group throughout the 24h period.
Serum P04 was significantly lower in the 1°HPT patients pre 
treatment throughout the 24h (p<0.001). A marked
synchronized rhythm in phosphate was observed in all groups 
with a transient decrease following the evening meal, which 
was the main meal of the day, a significant nocturnal rise 
and early morning fall being seen in all groups. The 
percentage change in phosphate during the 24h was greater 
in normal subjects and post treatment than in those with 
1°HPT pre treatment.
3.4.4 Discussion
This study has shown that the circadian rhythm for PTH (1- 
84) and NcAMP which is present in normal males is not 
present in patients with 1°HPT but can be restored by 
surgical removal of the parathyroid adenoma. Although the 
profile of PTH (1-84) and NcAMP secretion is different in 
patients post parathyroidectomy compared to normal males a 
statistically significant circadian rhythm is restored 
following operation. The subtle differences in the shape 
of the profiles may reflect age and sex differences between 
the groups not just the presence or absence of a single 
pathology. Biological activity of PTH (1-84) has also been 
restored to normal post operation as judged by NcAMP 
production and PcAMP profiles although examination of 
individual profiles detects two patients whose biological 
response remains blunted. In these two patients cosinor
90
Phosphate
mmol/L
l .50-1
Normal Males
1.25-
1.0 0 -
0.75-
0.50
1: 2130 0130 0530 0930 13301
.50 i
Pre Surgery
1.25 -
1.00 -
0.75 -
0.50
1330 1730 2130 0130 0530 0930 1330
1.50
Post Surgery
1.25
1.00
0.75
0.50
1330 1730 2130 0130 0530 0930 1330
Time 24h Clock
Figure 15 Serum phosphate in normals, and 1°HPT patients
pre and post parathyroidectomy. Results are
expressed as mean ± SEM.
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analysis of individual rhythms indicates a low mesor and 
non significant amplitude for both PTH (1-84) and NcAMP. 
It is possible that this is a refection of both the length 
of time these patients were hyperparathyroid and the time 
from operative removal of the adenoma.
These observations raise important questions for the 
control of PTH (1-84) secretion in normal and abnormal 
states and the subsequent action of PTH (1-84) at its 
receptor. Previous studies have demonstrated a fall in 
ionised calcium during the night in both normal subjects 
and patients with 1°HPT (159). In this study we have also 
shown a transient but significant lowering of adjusted Ca 
in all groups between midnight and 02 0Oh. The aetiology of 
such a transient fall in calcium remains unclear. A 
reduction in ionised calcium might be expected to trigger 
a compensatory surge in PTH (1-84) secretion and therefore 
provide the mechanism of the nocturnal rise in PTH (1-84) 
in normal subjects and the subsequent increase in NcAMP. 
However, this explanation appears to be an over 
simplification, for it is known that continuous infusion of 
calcium into normal subjects at a dose just sufficient to 
obliterate the nocturnal fall in serum calcium does not 
eliminate the nocturnal rise in PTH (13 0). Predictably, 
infusion of calcium at higher doses leads to decreased 
nocturnal PTH secretion (130,131). Methodological problems 
also exist with the measurement of ionised calcium that 
make interpretation of previous data difficult as protein
91
effects may be contributing to changes in measured ionised 
calcium (169) . Clearly, therefore, factors other than 
changes in ionised calcium concentration are important in 
generating the circadian rhythm of PTH (1-84) in normal 
subj ects.
Patients with primary hyperparathyroidism have been shown 
to respond to the lowering of serum calcium with increased 
PTH secretion (170,171). It has been suggested that the 
basis of 1 °HPT is an alteration in the calcium-PTH set 
point rather than autonomous secretion of PTH by the 
parathyroid gland (172,173,174). In this study the absence 
of a synchronised nocturnal increase in PTH (1-84) in 
hyperparathyroid patients pre-op has been shown, despite 
the detection of a transient lowering in adjusted calcium 
consistent with the previous data on ionised calcium (159). 
Although the precise incremental fall in serum calcium 
required to produce a response in hyperparathyroidism has 
not been defined in these patients, this is further 
evidence against the fall in calcium being the sole trigger 
to circadian changes in PTH (1-84).
If changes in calcium concentration do not fully explain 
the circadian rhythm of PTH (1-84) then the influence of 
phosphate must also be considered. This study demonstrates 
a pronounced circadian rhythm of phosphate in normal 
subjects and 1°HPT post parathyroidectomy. A small 
decrease in phosphate which may be due to the movement of
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phosphate intracellularly to support carbohydrate 
metabolism, occurs following the evening meal. This small 
decrease is followed by a much larger increase in phosphate 
prior to the nocturnal surge of PTH (1-84). This increase 
in phosphate could be regarded as the stimulus for PTH 
release, which in turn would cause phosphaturia and the 
observed subsequent fall in serum phosphate. Abolition of 
the phosphate rise by fasting, until recently (Chapter
3.3), was believed to have no effect on PTH secretion with 
claims that the nocturnal surge persists after a short fast 
(13 0). Furthermore, infusion of calcium in an appropriate 
dose results in suppression of PTH secretion and an 
exaggerated phosphate circadian rhythm (13 0,131). Thus it 
would appear that phosphate has little or no influence on 
secretion of PTH throughout the night, but that the PTH 
status of the individual may well influence the extent of 
the phosphate circadian rhythm. Further support for this 
conclusion is obtained from the phosphate results in the 
hyperparathyroid patients in this current study, for the 
phosphate rhythm is attenuated in the presence of 
consistently elevated PTH (1-84) concentrations.
An important incidental observation from this study is that 
the discrimination between normal subjects and patients 
with primary hyperparathyroidism is time dependent. Thus, 
using PTH (1-84) as the discriminant, the optimal time for 
sampling is 1000-1600h when the variability within and 
between normal subjects is at its minimum. Similarly, this
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data suggests that the optimal time for sampling using 
NcAMP as the discriminant is between 1100-1500h and not 
early in the morning as recommended by previous authors 
(46,175) .
The profile of PcAMP excretion is remarkably consistent 
between the three groups studied. 1°HPT patients have a 
significantly increased mean PcAMP throughout the 24h 
period presumably reflecting increased PTH (1-84) 
concentrations. It would appear that hormones making the 
major contribution to the daily variations in PcAMP, and 
hence the pattern of PcAMP secretion, are relatively 
unaffected by the development of 1°HPT.
Further study is required to establish whether the loss of 
the circadian rhythm of PTH (1-84) and NcAMP in 1°HPT is an 
early event in the natural history of the disease or 
whether it is a secondary consequence of increases in the 
plasma calcium beyond critical threshold concentrations. 
It will also be important to discover whether or not 
restoring the circadian rhythms of PTH (1-84) and NcAMP in 
patients post parathyroidectomy has any significance for 
the metabolic bone disease observed in patients with 1°HPT.
Combining all the currently available data leads to the 
conclusion that changes in calcium and phosphate, either 
alone or in combination, can not fully explain the 
circadian rhythm of PTH (1-84) and parallel changes in
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NcAMP. A component of neuroendocrine control may exist and 
concerted effects of hormones are probably required to 
control the end organ responses and cAMP generation.
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Chapter 4
The Effects of Thyroid Status on cAMP Metabolism
96
4.1.1 Introduction
Alterations in calcium and skeletal metabolism are well 
recognised in patients with thyroid disease. Prolonged 
hyperthyroidism is associated with negative calcium 
balance, increased bone turnover, reduced bone density, 
decalcification and fractures (176,177,178,179,180,
181) . Hypothyroidism is characterised by decreased rates 
of skeletal turnover (177,182,183) and treatment of 
hypothyroidism results in a rapid decrease in bone density 
in some patients (184). The precise mechanisms for these 
changes are still poorly understood and conflicting 
evidence exists on the concentrations of immunoreactive 
parathyroid hormone (iPTH) present and cAMP metabolism in 
thyroid disease. In hyperthyroidism some studies have 
demonstrated suppressed iPTH (180,185,186,187) , others have 
observed no change in iPTH concentration (181,188,189) and 
more recently no change in intact PTH (190). Several 
groups have reported an increased excretion of UcAMP in 
hyperthyroidism (28,191,192) and an elevated PcAMP 
(28,189,193). An elevated UcAMP contrasts with suppressed 
iPTH since UcAMP is mainly dependent on PTH activity 
(45,54,61). However, as discussed earlier, it is more 
correct to determine NcAMP as an index of PTH action at the 
kidney (67,46) and a study measuring NcAMP has found lower 
concentrations in patients with hyperthyroidism (18 9).
Some authors have argued that alterations in thyroid status 
modify the end organ responses to PTH with claims that
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excess thyroid hormone sensitizes and deficient thyroid 
hormone blunts the responsiveness of bone to PTH (187) and 
that hypothyroidism impairs the renal response to PTH 
(147) .
Comparison of previous studies is complicated by the fact 
that the immunoassays used to measure PTH have been 
relatively insensitive and of variable specificity. The 
recent development of immunoradiometric assays
(100,101,129) measuring intact PTH (PTH 1-84) has improved 
clinical discrimination in diseases of calcium metabolism 
(101,156) and has enabled small changes in PTH (1-84) 
concentration to be demonstrated even within the reference 
interval (Chapter 3, 134) . In this chapter the
relationship between serum PTH (1-84) concentrations and 
indices of PTH activity in thyrotoxic, hypothyroid, treated 
hypothyroid patients and euthyroid controls has been 
examined.
4.1.2 Patients and Methods
All patients were attending a thyroid outpatient clinic. 
In total 3 5 newly diagnosed hyperthyroid, 2 0 newly 
diagnosed hypothyroid, 35 treated hypothyroid patients and 
3 0 euthyroid volunteers were studied. Hyperthyroidism, 
hypothyroidism or euthyroidism was diagnosed following 
clinical examination, estimation of total thyroxine (TT4) , 
total triiodothyronine (TT3) , thyroid stimulating hormone 
(TSH), thyroid antibodies and, where appropriate, thyroid
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scan. Hypothyroid patients all received treatment with 
thyroxine following diagnosis. All treated hypothyroid 
patients had received thyroxine replacement therapy for a 
minimum of 3 months and were considered to be clinically 
euthyroid with thyroid function tests within the reference 
ranges for a patient on thyroxine (194) . In this study 
measurements of TT4/ TT3/ TSH, PTH(l-84), PcAMP, UcAMP, 
serum albumin, serum and urine calcium, phosphate and 
creatinine were performed on appropriate samples as 
outlined Chapter 2. NcAMP was calculated by the method of 
Broadus et al (4 6) and serum calcium adjusted for albumin 
as described previously (106). Statistical analysis was 
performed using a Kruskal Wallis (ANOVA) test to detect 
significance for each measurement for the four study groups 
prior to applying the Mann-Whitney U-test to compare 
between group significance.
4.1.3 Results
The thyroid function test results for each category of 
subject studied are given in Table 7. These results 
confirm biochemical hyperthyroidism, hypothyroidism and 
euthyroidism. The expected increased mean TT4 and decreased 
TSH is observed in patients receiving thyroxine replacement 
therapy (194).
PTH (1-84) concentrations and NcAMP are shown for 
comparison in the scattergrams (Figure 16) . As can be seen 
PTH (1-84) was undetectable (<0.5 pmol/L) in 10/35 patients
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Figure 16 PTH (1-84) and NcAMP in euthyroid, thyrotoxic, 
hypothyroid and thyroxine treated hypothyroid 
subj ects.
with hyperthyroidism and in 8/3 0 treated hypothyroid 
patients for the purposes of statistical comparison 
patients with undetectable PTH (1-84) have been assigned a 
value of 0.5 pmol/L. PTH (1-84) is elevated in 6/20 
patients with hypothyroidism. In contrast NcAMP is 
undetectable in only 6/35 hyperthyroid patients and in only 
2/35 treated hypothyroid patients. In hypothyroid patients 
NcAMP is lower than would be predicted by the PTH (1-84) 
concentrations with only 2/20 patients having elevated 
NcAMP.
Table 8 shows the values obtained for adjusted Ca, 
calcium/creatinine ratio, PcAMP and UcAMP in the subjects 
studied. Significant differences for these measurements 
are given for comparison between thyrotoxic, hypothyroid, 
treated hypothyroid patients or euthyroid controls. 
Hypercalcaemia was present in 8 patients with 
thyrotoxicosis. PTH (1-84) was undetectable in these 8 
patients. All treated hypothyroid patients were
normocalcaemic.
4.1.4 Discussion
Modern assays for serum PTH (1-84) overcome the sensitivity 
problems experienced in earlier studies of PTH in thyroid 
disease. It is clear from these results that mean intact 
PTH concentrations are decreased in thyrotoxicosis and 
increased in hypothyroidism. In thyrotoxic patients the 
relative decrease in PTH (1-84) would appear to be a
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physiological response to an increase in mean serum Adj Ca. 
8 thyrotoxic patients with PTH (1-84) values below the 
detection limit were hypercalcaemic (Adj Ca >2.6 mmol/L) 
and the mean Adj Ca level was increased relative to 
controls in thyrotoxicosis. This increase in serum calcium 
is probably due to Ca release from bone as a result of 
direct effects of endogenous thyroid hormones on skeletal 
metabolism. PTH (1-84) is the active circulating form of 
PTH and in thyrotoxic patients indices of PTH activity are 
consistent with decreased serum PTH (1-84) concentrations: 
NcAMP is decreased, TmP04/GFR is elevated and Ca/Cr ratio is 
elevated.
In hypothyroid and treated hypothyroid patients the 
correlation between PTH (1-84) and indices of PTH activity 
is weaker. Hypothyroid patients have relatively higher PTH 
(1-84) levels than euthyroid controls and this is 
associated with normocalcaemia. NcAMP is lower than 
expected for the observed PTH concentrations, TmP04 is 
higher and Ca/Cr ratios lower than normal. These indicate 
that there is relative end organ resistance to PTH (1-84) 
in hypothyroid patients.
Impaired responses to exogenous PTH have been demonstrated 
in hypothyroid patients (187,147) and the reasons for this 
may be due to the effects of thyroid hormone status on 
adenyl cyclase (14 9,195) and cAMP phosphodiesterase 
activity (148,149,196). Hypothyroid animals have decreased
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adenyl cyclase with either increased or normal 
phosphodiesterase activity which results in decreased cAMP 
production. It is likely that cAMP production is affected 
similarly in all cells and this would explain the increased 
PTH (1-84) observed in hypothyroid patients but absence of 
hyperparathyroid symptoms.
Hypothyroid patients on thyroxine have a mean PTH (1-84) 
concentration that is lower than normals. This is 
associated with a relatively increased NcAMP, a lower TmP04, 
a non statistically significant higher mean Ca/Cr ratio and 
normocalcaemia. Thyroxine therapy has been associated with 
reduced bone density (184,197) and it has been suggested 
that this may be due to either increased sensitivity to PTH 
or a direct effect of exogenous thyroid hormones (198). 
These results would indicate that at the kidney, although 
PTH (1-84) is lower than normal, cAMP production is 
increased. This may be due to an increase in adenylate 
cyclase activity and a decrease in cAMP phosphodiesterase 
activity, as has been observed when hypothyroid rats were 
treated with thyroxine (148). The cAMP responses observed 
are therefore likely to be secondary to thyroxine therapy 
and the decreased PTH (1-84) concentrations a consequence 
of thyroxine action on skeletal metabolism. The
combination of relative PTH suppression and thyroxine 
induced bone resorption resulting in osteopenia.
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These observations have demonstrated the significant 
changes in intact PTH concentrations that occur in thyroid 
disease and when taken in conjunction with indices of PTH 
activity help to explain the mechanisms involved in calcium 
metabolism in these patients. Treated hypothyroid patients 
have subtle differences from euthyroid controls that may 
begin to explain why these patients have a relatively 
reduced bone density. Whether these differences are the 
result of over replacement with thyroid hormones or simply 
a consequence of the differences between endogenous thyroid 
hormone production and exogenous thyroxine therapy will 
require further investigation.
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Chapter 5
Adrenocorticotrophic and Glucocorticoid 
Effects on Plasma and Urine cAMP
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5.1 Adrenocorticotrophin Effects on Plasma cAMP
5.1.1 Introduction
The list of hormones whose effects are mediated through 
cAMP or can modify cAMP mediated events continues to 
increase. Most of the data on cAMP production has been 
obtained by studying in-vitro systems and the knowledge on 
in-vivo effects of many hormones is minimal. This is 
particularly true of the effects of glucocorticoids and 
those hormones involved in the hypothalamic-pituitary- 
adrenal axis.
The synthesis of steroid hormones involves up to five 
different steroid hydroxylases belonging to the cytochrome 
P450 superfamily (199) and the rate limiting reaction is 
catalysed by an enzyme complex comprising adrenodoxin 
reductase, adrenodoxin and cholesterol side-chain cleavage 
cytochrome P450 (P450scc) . Synthesis of P450scc is induced by 
adrenocorticotropin (ACTH) through the mediation of cAMP 
(2 00). Evidence for the role of cAMP in steroidogenesis 
has accumulated over many years. Early observations on the 
effects of exogenous cAMP (201,202), then ACTH action on 
adrenal quarters (203) and perfusion of adrenal cells (204) 
all suggest an important role for cAMP in the control of 
adrenal steroid production. Most recent data suggests that 
cAMP activates cAMP-dependent protein kinases and these are 
capable of activating pathways linked to the stimulation of 
steroidogenesis (205,206,207,208).
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Bovine adrenocortical cells in primary culture respond to 
ACTH and adrenaline stimulation by increasing intracellular 
cAMP and releasing cAMP into their culture medium (209). 
The rate of release of cAMP from ACTH stimulated adrenal 
cells is slower (204) than that observed from PTH 
stimulated renal cells (55) which suggests that a time 
delay in cAMP production may exist in adrenal cells or that 
the rate of release via the cell membrane is slower in such 
cells. It is conceivable that circulating cAMP in plasma 
may be affected by ACTH secretion and that supra 
physiological doses, such as those used during a synacthen 
test, may cause an increase in circulating cAMP. Initially 
in this chapter cAMP production in normal subjects in 
response to ACTH administration has been studied.
5.1.2 Subjects and Methods
23 healthy volunteers (age 18-59, mean 32, 14 male, 9
female) were studied after an overnight fast. A venflon 
cannula 18G was inserted in a vein in the ante cubital 
fossa at 0900h. All subjects remained seated throughout 
the test and consumed no food or drink during the test. At 
lOOOh a baseline blood sample (10 ml) was taken prior to 
intra-venous injection of 0.25 mg Tetracosactrin 
(Synacthen) in 5 ml sterile water via the cannula. Further 
blood samples were obtained at 2.5, 5, 10, 15, 30, 60 min 
following synacthen injection. 8 of the above volunteers 
were sampled on a second occasion after insertion of a 
venflon cannula in the median cubital fossa with the
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cannula flushed with saline after each sample. Plasma 
cortisol, cAMP and PTH (1-84) were measured as described 
previously. Statistical analysis was performed using 
paired t-test within each study and Mann-Whitney U test 
between studies.
5.1.3 Results
Figures 17 and 18 show the cortisol, PcAMP and PTH (1-84) 
response in the subjects studied during the control period 
and following administration of synacthen (mean ± SD) . The 
time profile for the increase in both plasma cortisol and 
cAMP are similar for Synacthen with a significant elevation 
of these analytes occurring 5 min after Synacthen 
injection. Cortisol and PcAMP continue to increase over 
the 60 min following Synacthen injection. The magnitude of 
the responses are different with the plasma cortisol 
doubling after 3 0 min and PcAMP increasing by approximately 
30% over the same period of time. There is no significant 
change in cortisol or PcAMP in the control study and no 
significant differences in PTH (1-84) in either study 
period. Individual cortisol and PcAMP responses following 
Synacthen are shown Figure 19 which demonstrate the 
consistency in response in all the subjects studied.
5.1.4 Discussion
A highly consistent response to Synacthen is observed in 
all subjects studied with a remarkable similarity in the 
timing of the profiles for both cortisol and PcAMP. It
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Figure 19 Individual cortisol and PcAMP responses to 
0.25 mg synacthen in normal subjects.
would be expected that if Synacthen was the major stimulus 
to PcAMP release the rise in PcAMP would have occurred 
earlier than the rise in cortisol and would be much shorter 
in duration than the cortisol rise. The rise in PcAMP 
after PTH infusion is immediate and the peak cAMP response 
is observed within 5-10 min, reflecting the short half life 
of PTH and the transient receptor mediated generation of 
cAMP (55). In contrast the PcAMP response to Synacthen is 
delayed until cortisol rises at 5 min, parallels the rise 
in cortisol and remains elevated at 60 min.
PTH (1-84) secretion remains unaffected by either Synacthen 
injection or cortisol secretion in this study and so the 
changes in PcAMP observed are not due to PTH mediated cAMP 
generation. From the data available it would appear that 
the increase in PcAMP that occurs following synacthen 
injection is due to cortisol production and a general 
systemic effect rather than the action of Synacthen on the 
adrenal. Glucocorticoids are known to enhance cAMP 
accumulation in cell cultures (210) which may be due to 
increased receptor number (211,212,213) or reduced 
phosphodiesterase activity (145,214,215,216,217), although 
most of these effects require prolonged exposure to the 
steroid for a period greater than 12h.
The short term effects of glucocorticoids resulting in 
secondary hyperparathyroidism reported by Fucik et al (218) 
have not been confirmed by this current experiment and this
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may be a reflection of the relatively lower level of 
endogenous cortisol produced following Synacthen injection 
compared to the rise in glucocorticoid observed following 
administration of exogenous glucocorticoid. Chronic 
exposure to glucocorticoids in man also results in 
increased secretion of PTH (219) and so the available data 
would appear to indicate that in order to stimulate PTH 
secretion glucocorticoids need to be administered at 
relatively high concentrations or for a long period of 
time.
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5.2 Glucocorticoid Effects on cAMP Metabolism
5.2.1 Introduction
Enhanced cAMP accumulation in response to hormone 
stimulation has been observed in several cell types when 
glucocorticoids are added to culture media (210) . The 
mechanism of this effect varies amongst cells of different 
tissues. In astrocytoma, neutrophil and human lung cells 
glucocorticoids increase the number of /3-adrenergic 
receptors (211,212,213). In fibroblast, hepatoma,
lymphocyte and a variety of bone derived cell types there 
is a reduction in phosphodiesterase activity in response to 
glucocorticoids (145,214,215,216,217) . In the osteosarcoma 
cell line dexamethasone increases adenylate cyclase 
activity (220,221), increases hormone receptors and the 
abundance of the regulatory Gs protein (222) .
Most of the observed effects of glucocorticoids on cAMP 
production by cultured cells require exposure to the 
steroid for a minimum of 12h and the continued presence of 
steroid during hormonal stimulation. Some authors have 
reported increased cAMP generation in eukaryotic cells 
(223,224,225) and erythrocytes (226) when exposed for short 
time periods (5-60 min) to pharmacological concentrations 
of glucocorticoids.
Little is known about the in-vivo effects of 
glucocorticoids on cAMP production, although this has
110
obvious importance for patients receiving glucocorticoid 
therapy. One study has failed to demonstrate any effect of 
acute or chronic treatment with dexamethasone on the PTH- 
induced rise of cAMP by rat kidney (227) but it has been 
reported that acute and chronic glucocorticoid treatment in 
man results in secondary hyperparathyroidism (218,219) and 
this would be expected to increase cAMP production.
In this section of Chapter 5 the acute effects of 
dexamethasone, given as part of a standard overnight 
dexamethasone suppression test, on PTH (1-84), plasma, 
urinary and nephrogenous cAMP have been investigated.
5.2.2 Subjects and Methods
21 healthy volunteers were studied (age 17-61 years, mean 
31, 14 male, 7 female) on two consecutive mornings pre and 
post an overnight Dexamethasone suppression test (2 mg 
dexamethasone orally at 2300h). Each subject acted as 
his/her own control and emptied their bladder at 23 00h then 
collected all urine voided until 0900h the next morning. 
A blood sample was obtained by venesection at 0900-0930h. 
All biochemical measurements were performed as described 
previously. Statistical comparisons were performed using 
the paired t-test.
5.2.3 Results
Table 9 compares the results obtained in the control period 
and post dexamethasone. Dexamethasone caused a significant
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decrease in urine cortisol, total UcAMP and NcAMP but had 
no effect on PTH (1-84) or PcAMP obtained at 0900h in the 
morning following dexamethasone. The individual responses 
to dexamethasone for cortisol, NcAMP, UcAMP and PcAMP are 
given in Figures 20 and 21 which confirm that all subjects 
studied responded to dexamethasone by suppressing urinary 
cortisol and 18 out of 21 decreased NcAMP production. 
PcAMP showed the greatest variability with an increase in 
PcAMP observed in 12 and a decrease in 9 subjects.
5.2.4 Discussion
Dexamethasone resulted in the well recognised suppression 
of urinary cortisol in all subjects studied (228,229).
Associated with this effect was a significant decrease in 
total UcAMP and NcAMP. Although a variable response in 
PcAMP was observed, overall there was no significant
difference in PcAMP following dexamethasone. The main
contributor to the decrease in total UcAMP was the
nephrogenous component. The significant decrease in NcAMP 
may be due to a number of factors. NcAMP production will 
decrease in response to a decrease in a) plasma PTH 
concentration b) the number of PTH receptors on the renal 
tubular cell surface c) PTH receptor recycling and d) 
adenylate cyclase activity. Cyclic AMP breakdown may be 
enhanced by an increase in phosphodiesterase activity or by 
alterations in the renal handling of cAMP.
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In this study the significant effects on cAMP metabolism 
may be caused directly by dexamethasone or indirectly 
through the resultant decrease in cortisol. Studying the 
effects of these hormones on cAMP production in-vitro and 
in animal models has given conflicting results. In cell 
culture systems dexamethasone enhances cAMP production 
(222) whilst in rat kidneys dexamethasone has little effect 
on the PTH mediated generation of cAMP (227) . 
Hydrocortisone and dexamethasone has been shown to enhance 
the response of ROS 17/2.8 cells in culture to PTH 
resulting in a dose-dependent increase in cAMP production 
(220,221). The current study suggest that the decrease in 
circulating cortisol in response to dexamethasone may have 
caused the decrease in NcAMP possibly by altering the 
kidney cell response to PTH.
At the time this study was being performed the detailed 
knowledge on the circadian rhythm of PTH (1-84) was not 
known and so the possibility exists that the dexamethasone 
test acutely suppresses PTH (1-84) secretion and interferes 
with the nocturnal rise in PTH (1-84) resulting in the 
decrease in NcAMP production. However, the failure of the 
increase in cortisol in response to Synacthen to influence 
PTH secretion acutely (Chapter 5.1) would suggest that this 
is unlikely. PTH (1-84) measurements were not
significantly different at 0900-0930h but this does not 
exclude the possibility of overnight effects and so further 
study is required to fully explain these findings.
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In view of the apparent failure of hydrocortisone to 
suppress the action of PTH in patients with 1°HPT 
(Hydrocortisone or Steroid Suppression Test, 
230,231,232,233) together with the results of this study 
and the ACTH stimulation study it would appear that 
dexamethasone and cortisol effects on cAMP metabolism in 
humans merit further study.
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Chapter 6
PTH(1-84), PTHrP and cAMP in 
Primary Hyperparathyroidism
115
6.1.1 Introduction
Total urinary cAMP (UcAMP) is a combination of filtered 
cAMP derived from the circulation and cAMP produced by the 
kidney, nephrogenous cAMP (NcAMP). Between 4 0-45% of the 
UcAMP and 90-95% of the NcAMP is produced as a consequence 
of PTH action on the kidneys (46,67,68). NcAMP has been 
proposed as an accurate indicator of PTH function but 
published positive correlations between immunoreactive PTH 
and either UcAMP or NcAMP, although always significant, 
vary from strong to weak (r = 0.76 to r = 0.31)
(46,67,69,71,93). There are a number of possible reasons 
for the variability and low correlations observed. 
Immunoassays for PTH used in the 1970s and early 1980s were 
subject to several technical and biological problems, 
including the heterologous nature of the assays and the 
heterogeneity of circulating forms of PTH. This meant that 
the assays often measured inactive fragments of PTH which 
may be present in the circulation especially in patients 
with renal impairment. Inaccuracy in the measurement of 
PTH is likely to be an important factor in the variable 
correlations with NcAMP.
Hyperparathyroidism with persistent elevations of PTH 
results in a down regulation of PTH receptors with a 
reduced cAMP and phosphaturic response to PTH stimulation 
(234,235,236,237,238,239). The precise length of time 
required to develop this down regulation and its effect on 
basal NcAMP production in 1°HPT is unknown but infusion of
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bovine PTH for 2h at a rate of 500 units/h results in 
impairment of the cAMP response to PTH injection which 
lasts for 12-18h (234,236).
There are several problems inherent in NcAMP estimations as 
outlined in chapters 1,2 and 3. Inaccuracy may be 
introduced due to marked PcAMP variability and unrecognised 
spikes in PcAMP concentrations (Chapter 3) . Consistency in 
duration and timing of both urine and plasma sampling is 
required to eliminate variability. Measurement of cAMP has 
to be performed with as precise and specific an assay as 
possible with sample dilutions targeted at the part of the 
immunoassay curve which results in the best assay 
precision.
Calcitropic hormones other than PTH may also play a role in 
NcAMP production in 1°HPT. Immunoassays for parathyroid 
hormone related protein (PTHrP) have recently been 
developed and some authors have detected elevated levels of 
PTHrP in a high percentage of patients with 1°HPT (240). 
Parathyroid adenomas have DNA and mRNA for PTHrP present in 
significant quantities as well as expressing PTHrP 
(241,242,243). There is also evidence to suggest that 
fetal parathyroids express PTHrP in preference to PTH and 
that PTHrP is the major fetal calcitropic hormone in some 
species (244,245). It is therefore possible that PTHrP may 
be secreted by the parathyroid gland in 1°HPT and this 
would affect PTH correlations with NcAMP.
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Recent advances in assay technology has led to the 
development of immunometric assays which measure the intact 
molecule of PTH (PTH (1-84)) without interference from PTH 
fragments. The sensitivities and specificity of these 
assays allows PTH (1-84) to be measured in the low 
picomolar range and has improved the discrimination between 
normals and patient groups such as 1°HPT, HCM, 
hypoparathyroid and secondary hyperparathyroidism 
(100,101,129). Immunoradiometric assays for PTHrP have 
also recently become available (Chapter 9) with excellent 
specificity and sensitivity and so it is now possible to 
evaluate the relationship between PTH (1-84), PTHrP and 
cAMP metabolism in patients with 1°HPT.
6.1.2 Patients and Methods
Over a two year period 62 patients with 1°HPT were 
prospectively included in the study. There were 24 males 
and 38 females (29 - 82 years, mean 56) . All patients were 
hypercalcaemic on more than one occasion (calcium adjusted 
for albumin greater than 2.65 mmol/L) with a PTH (1-84) 
concentration on the same specimen greater than 3.0 pmol/L. 
In 46 patients an adenoma or hyperplastic parathyroid 
glands have been removed surgically, in 48 patients an 
adenoma was detected either by ultrasound or by 
technetium/thallium subtraction scan, in 16 patients the 
diagnosis is currently based on the clinical, radiological 
and biochemical findings since these patients have negative 
technetium/thallium scans and are unwilling or unfit for
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operation. In 4 of 16 patients a previous selective venous 
catheterisation of the neck veins indicated an increase in 
iPTH on the left side of the neck.
Blood samples were obtained by standard venesection in the 
middle of a timed urine collection obtained between 0900- 
1400h. All patients were asked to void urine prior to 
collection of the timed sample (4h) which was obtained by 
spontaneous voiding. Patients remained recumbent for at 
least 15 min prior to blood sampling and were allowed to be 
ambulant but avoided exercise throughout the time of the 
urine sample collection. Blood was collected into tubes 
containing lithium heparin, EDTA, EDTA with protease 
inhibitors and no anticoagulant. Plasma was separated
within 30 min and stored frozen -70°C prior to analysis. 
Serum was obtained after 30-45 min and stored either frozen 
(-70°C) or refrigerated (4°C) prior to analysis. All urine 
voided during the timed collection period was collected in 
one sterile container containing no preservatives, volumed 
and an aliquot stored frozen (-20°C) prior to analysis.
PTH (1-84), plasma and urine cAMP, PTHrP and routine 
chemistries were all measured as described in Chapter 2. 
NcAMP was calculated as described by Broadus et al (46). 
Statistical differences between groups was evaluated using 
the Mann-Whitney test and correlation coefficients were 
determined as described Chapter 2.
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A subgroup of 12 patients with proven 1°HPT were followed 
for a period of 6 months. Patients were selected 
prospectively and randomised into a double blind placebo 
controlled study to receive either placebo or 100 mg 
atenolol daily for 6 months. Patients were sampled monthly 
as described previously and within group comparison of data 
performed using Student's paired t-test and between groups 
comparison by Mann-Whitney test.
6.1.3 Results
The baseline values for Adj Ca, P04/ PTH(l-84), PTHrP,
PcAMP, UcAMP and NcAMP are given in Table 10. Adj Ca, PTH 
(1-84) , PcAMP, UcAMP and NcAMP were higher than the 
reference range in 100%, 87%, 24%, 81% and 90%
respectively. P04 was lower than the reference range in 16% 
of patients. PTHrP was increased above the reference range 
(2.7 pmol/L) in only 2 patients (3%), was above the assay 
detection limit (0.7 pmol/L) in another 5 (8%) and was
below the assay detection limit in the remaining 55 
patients (89%).
The correlation of PTH (1-84) with NcAMP is shown in Figure 
22a. It is notable that a subset of patients exist 
(outlined in Figure 22a) whose NcAMP values are such that 
they appear discordant with the measured PTH (1-84) . In 
all cases the level of NcAMP is far higher than expected 
for the measured PTH (1-84) . If this group of patients are 
removed from the analysis the r value for the correlation
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Figure 22 Linear regression of PTH (1-84) and NcAMP in 
1°HPT patients a) including all results 
obtained b) excluding results were NcAMP is 
deemed inappropriate for PTH (1-84) .
between PTH (1-84) and NcAMP increases (Figure 22b) . In 
one of the patients in this subgroup PTHrP was elevated and 
if the PTHrP and PTH (1-84) values for that patient are 
added together (assuming PTHrP and PTH (1-84) to be 
biologically equipotent in-vivo) the correlation with NcAMP 
for that patient is much stronger. A plot of PTHrP added 
to PTH (1-84) for all patients where the measurements are 
available is shown Figure 23. The correlation obtained in 
this comparison is little different from that obtained when 
PTH (1-84) and NcAMP are compared for all patients studied. 
The variation in PTH (1-84), NcAMP (Figure 24), UcAMP and 
PcAMP (Figure 25) for the 12 patients studied over a 6 
month period are shown for placebo and atenolol treated 
patients. Although the variability in PTH (1-84) was 
greater than that in NcAMP, reflecting the greater error of 
estimation for NcAMP, there was remarkably little 
difference in the values obtained in the majority of the 
patients over the study period. No significant difference 
in any measurement was observed between the two groups at 
any time point. Correlations between PTH (1-84) and NcAMP 
for this group of 12 patients remained remarkably 
consistent throughout the period of study in both placebo 
(P1-P6) and atenolol (P7-P12) treated patients (Figure 26) . 
In particular 2 patients who had NcAMP that was identified 
as inappropriate for the PTH (1-84) maintained the same 
correlations over the period of study whether receiving 
placebo or atenolol (Figure 26).
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Figure 23 Linear regression of PTH + PTHrP and NcAMP 
1°HPT patients.
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Figure 26 Correlation of individual values for PTH (1-84) 
and NcAMP in 12 patients (Pi-Pi2) with 1°HPT 
sampled monthly for 6 months.
6.1.4 Discussion
Correlations between PTH and NcAMP have varied markedly in 
published studies although they have always been positive 
and significant (46,67,69,71,93) . In this study one of the 
strongest and highly significant correlations between the 
two measurements has been obtained and this is due to a 
number of factors.
Improvement in the measurement of PTH with estimation of 
the major circulating biologically active molecule PTH (1- 
84) is a major factor. The current generation of PTH (1- 
84) IRMAs are able to measure the intact PTH molecule with 
excellent specificity and accuracy without interference 
from fragments of PTH (100,101,129) and should therefore 
correlate better with the in-vivo biological estimate of 
activity NcAMP. It is possible that PTH (1-34) could 
contribute to biological effects but in studies performed 
on humans using infused PTH (1-34) the half life of this 
molecule was found to be relatively short (t 1/2 = 2.5 min) 
and in all subjects measured to date, including patients 
with 1°HPT, PTH (1-34) circulating concentrations were < 
0.5 pmol/L (246) . It would appear that in most studies the 
molecule of major biological significance in-vivo is PTH 
(1-84) .
The current generation of RIAs for cAMP have excellent 
performance characteristics and will contribute to the 
improved correlation between PTH (1-84) and NcAMP.
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Variability in NcAMP is greater than that in PTH (1-84) , 
with repeated estimates, which is not surprising since 
NcAMP is a derived value calculated from 4 measurements. 
In those patients who were studied over 6 months there was 
little change in either the measurement of PTH (1-84) or 
estimate of NcAMP and the correlation between the two 
remained remarkably constant. This may in part be due to 
our use of urine collections over a relatively short time 
period under close supervision rather than 24h urine 
samples with the associated difficulty of ensuring accurate 
collections.
It is known that the presence of hypercalcaemia, Vitamin D 
abnormalities and 1°HPT can alter the cAMP response to PTH 
and down regulation of receptors will occur in patients 
with 1°HPT (234,235,236,237,238,239). In 12 patients 
studied for 6 months, however, there was little change in 
either PTH (1-84) or NcAMP in the majority of patients and 
this confirms that any changes that take place in 1°HPT 
probably occur very slowly over a long period of time.
An early study of PTHrP measurements in patients with 1°HPT 
indicated 3 0% of 1°HPT patients were producing PTHrP 
simultaneously with PTH (1-84) (240). In subsequent
studies with more specific and sensitive assays for PTHrP 
these initial findings have not been confirmed and taken 
overall only a small percentage of 1°HPT patients have 
circulating PTHrP levels of any significance (247,248,249,
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Chapter 8). In this current study only one patient had a 
PTHrP level that would be considered as significantly 
detectable and this was in one of the patients in whom 
NcAMP was inappropriate for the level of PTH (1-84) . 
Assuming equal biological potency in humans for equivalent 
concentrations of PTHrP and PTH (1-84) , then by addition of 
these two calcitropic hormones the NcAMP production was 
exactly as expected by the correlation statistics. 
However, PTHrP was low or undetectable in the majority of 
1°HPT patients in this study who had inappropriate NcAMP 
for their PTH (1-84) concentrations and in 2 of these 
patients the NcAMP production and PTH (1-84) concentrations 
remained relatively constant over a 6 month period. It is 
unlikely, therefore, that secretion of PTHrP by parathyroid 
adenomas plays a significant part in the abnormalities of 
calcium homeostasis that are observed in the majority of 
patients with 1°HPT. There was no obvious reason, in the 
remaining patients of this group, for the discordance 
between PTH (1-84) and NcAMP. It is possible that 
biologically active fragments of either PTH or PTHrP are 
produced by these patients which are not recognised by the 
IRMAs used in this study due to the epitopes that the 
antibodies employed in the assay detect. The only other 
significant difference observed was a lower PcAMP 
concentration in these patients (P1# P6, P7) when compared 
to the rest of the 1°HPT patients. This may indicate that 
the renal production of cAMP selectively appears mainly at 
the tubular luminal side of the renal cells or that other
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substances are circulating in some 1°HPT that can have 
predominant effects on renal cAMP production, perhaps by 
enhancing PTH (1-84) activity, whilst having little effect 
on PcAMP.
An increased prevalence of hyperparathyroidism in 
hypertensive patients has been reported (250) and also of 
hypertension in patients with 1°HPT (251,252,253). The 
precise mechanism of this hypertension is open to debate as 
the evidence for the role of hypercalcaemia (254,255,256), 
renal function (250,251,256), the renin-angiotensin system 
(255,257,258), the sympathetic nervous system (259) and a 
parathyroid hypertensive factor (PHF) (260) is conflicting. 
Treatment of 1°HPT patients with parathyroidectomy has 
variable effects on blood pressure when studies are 
compared. Some show improvement or cure (251,255,261) while 
others have found no significant change in blood pressure 
following surgery (258,262,263,264,265). Alterations in 
indices of calcium metabolism have been reported in 
hypertensive patients treated with either propranolol, 
bendroflumethiazide or verapamil (266) . Hvarfner reported 
an increase in ionised calcium and phosphate and decreased 
PTH (by RIA), free fatty acids and glycerol in hypertensive 
patients treated for 6 months with propranolol. This 
previous publication raised the possibility that /6-blockers 
might modify PTH secretion and calcium metabolism in 
patients 1°HPT. In this current study there was no 
significant effect of atenolol on any measurement related
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to calcium homeostasis, although a small number of subjects 
were studied over a relatively short period of time. 
Despite this it is obvious that atenolol has no important 
or dramatic effects on calcium homeostasis in the short 
term.
In this study a significant correlation between NcAMP and 
PTH (1-84) has been demonstrated that persists unchanged 
for a significant period of time in a selected group of 
1°HPT patients. A subgroup of patients exists where NcAMP 
production is apparently inappropriately high for the 
measured PTH (1-84) and in a very small percentage of 1°HPT 
patients this may be due to the simultaneous production of 
PTHrP. The main factor influencing the amount of NcAMP 
produced is the amount of circulating PTH (1-84) in 
patients with 1°HPT. The factors that can further 
influence the NcAMP produced for a consistent PTH (1-84) 
level are not immediately obvious and further study will be 
required to investigate these current findings in the 
future.
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Chapter 7
cAMP Response to Bisphosphonate Treatment
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7.1 Comparison of the Daily Variation in cAMP Following
Pamidronate in Patients with Hypercalcaemia Associated 
with Malignancy and Paget's Disease of Bone
7.1.1 Introduction
The bisphosphonates are a group of pyrophosphate analogues 
that are potent inhibitors of osteoclast-mediated bone 
resorption. They are used in the treatment of bone 
diseases associated with increased bone resorption such as 
Paget's disease (267,268,269,270,271), hypercalcaemia 
associated with malignancy (HCM) (272,273,274,275,276) and 
involutional osteoporosis (277). Pamidronate (3-amino-l- 
hydroxypropylidene-1,1-bisphosphonate, APD) is one of the 
more effective bisphosphonates in the treatment of Paget's 
disease and HCM and the effects of treatment on calcium and 
phosphate homeostasis have been well documented 
(272,273,274,276,278). There is no unifying theory that 
explains all the alterations in calcium and phosphate 
metabolism that occur following pamidronate treatment, and 
various mediators of the ionic changes have been postulated 
(278,279,280).
To date there have been no studies on the response of cAMP 
to pamidronate therapy and studies on PTH have been limited 
by assay technology with increases in plasma PTH only 
observed when patients became hypocalcaemic (279) .
128
7.1.2 Patients and Methods
12 patients with Paget's disease (4 male, 8 female, aged 
51-63 years) were studied. All had their bone disease 
confirmed by standard biochemical, radiological (X-ray, 
radionuclide bone scan) methods and, where appropriate, by 
histomorphometry. All were studied prior to and following 
a single intravenous dose of 45 mg pamidronate, which was 
given intravenously over 4h in 0.5 L of 0.9% NaCl.
12 patients with HCM (7 male, 8 female, aged 48-78 years, 
Adj calcium >2.7 mmol/L) were also studied. The origin of 
the primary tumour in these patients was breast (3) , 
myeloma (2) , lung (4) , lymphoma (2) and genito-urinary 
tract (1) . 8 of the 12 patients had metastatic bone
disease confirmed by radionuclide bone scan and the tumour 
load was estimated as being heavy in 2 and light in 6 
patients. All patients were rehydrated over a 24h period 
with a minimum of 2 L of intravenous 0.9% NaCl prior to the 
administration of a single intravenous dose of 3 0 mg 
pamidronate given over 4h in 0.5 L of 0.9% NaCl. Serum 
creatinine concentrations were within the reference range 
(60-130 i^mol/L) in 10 patients and elevated in 2 (150 and
18 0 jLimol/L) following rehydration. No patient developed 
renal failure during the study.
In both groups of patients blood samples were obtained by 
venesection prior to pamidronate treatment (day 0) and 
daily thereafter for 7 days. All blood specimens were
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collected between 1000 and llOOh, and a timed 2-4h fasting 
urine was obtained after discarding the first morning urine 
specimen (as discussed Chapter 3). Serum, K-EDTA plasma 
and urine were stored at -20°C prior to analysis.
All measurements were performed as described previously 
(Chapter 2) . Each series of samples for an individual 
patient was analysed within a single batch.
Statistical analysis was performed using a Kruskal Wallis 
(ANOVA) test to detect significance for each measurement 
for each day prior to applying a paired difference t-test 
to compare each sample point with the appropriate day 0 
result for the patient.
7.1.3 Results
The mean (± SEM) results for each measurement in the 
patients with Paget's disease are shown Figures 27 and 28. 
Prior to therapy, the mean concentration of all analytes 
was within the appropriate reference range. Following 
pamidronate therapy, there was a small significant decrease 
in serum adjusted calcium, within the reference range, on 
day 2 (p<0.01) which was sustained throughout the remainder 
of the study. A significant increase in NcAMP on day 4 
(p<0.01), PcAMP on day 5 (p<0.05) and UcAMP on day 3
(p<0.05). PTH (1-84) increased significantly from day 2 
(p<0.05) and continued to increase throughout the study 
reaching a final mean value more than twice the upper limit
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of the reference interval. TmP04/GFR decreased gradually to 
a trough on day 4 (p<0.001) and remained at this low value 
thereafter.
The mean (± SEM) results for the analytes measured in the 
patients with HCM are shown Figures 29 and 30. Following 
rehydration, but prior to pamidronate therapy, all patients 
had elevated concentrations of serum adjusted calcium 
(range 2.85-3.95 mmol/L). 9 patients had PTH (1-84)
concentrations below the assay detection limit (0.5
pmol/L), whilst the other 3 patients had concentrations at 
the low end of the reference range (0.9-1.1 pmol/L). 
Despite this suppression of PTH (1-84) , the mean NcAMP 
concentration was significantly increased and was
"inappropriate" for the PTH (1-84) in 8 patients. The mean
TmP04/GFR was also significantly decreased and was
"inappropriate" for the PTH (1-84) in 7 patients.
Following pamidronate therapy, there was a rapid, 
consistent and continuing decrease in the serum adjusted 
calcium in all patients, with the mean concentration 
reaching the upper limit of the reference range on day 5. 
PTH (1-84) concentrations remained suppressed for days 1-3 
but increased significantly on day 4 (p<0.05) and continued 
to increase, such that the mean concentration was above the 
reference interval at the end of the study. The NcAMP, 
PcAMP, UcAMP and TmP04/GFR responses to pamidronate therapy 
were complex. The initially subnormal TmP04/GFR decreased
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significantly, reaching a nadir on day 5 (p<0.001) before
increasing significantly on the final day of the study 
(p<0.01). NcAMP measurement showed a significant increase 
from the elevated basal concentration to a peak on day 5 
(p<0.01) and then decreased significantly from this value 
by day 7 (p<0.05). UcAMP had a similar profile to NcAMP
increasing significantly on day 5 (p<0.01) and decreasing
significantly from this value by day 7 (p<0.05). PcAMP
decreased significantly on day 3 (p<0.05) and increased
significantly on day 6 compared to day 0 (p<0.02).
No patient from either group became hypocalcaemic during 
the study (all adjusted calcium results s»2.20 mmol/L) . 
Serum phosphate concentrations decreased following 
pamidronate from 1.05 (± 0.04) to 0.76 (± 0.05) mmol/L in
Paget's disease and from 1.34 (± 0.06) to 0.62 (± 0.08)
mmol/1 in HCM (day 0 v day 7).
The concentrations of PTH (1-84) corresponding to adjusted 
calcium values obtained for each patient following 
pamidronate therapy are shown in Figure 31. The majority 
of patients with Paget's disease had detectable PTH (1-84) ; 
in only one sample (adjusted calcium 2.55 mmol/L) was PTH 
(1-84) undetectable. In patients with HCM having adjusted 
calcium concentrations greater than 2.85 mmol/L, only 9.8% 
of samples had detectable PTH (1-84) concentrations (1.0-
2.4 pmol/L); between 2.6 and 2.85 mmol/L, 75.9% of samples 
had detectable PTH (1-84); below 2.6 mmol/L, 93.6% of 
samples had detectable PTH (1-84) (0.8-19.0 pmol/L).
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Figure 31 PTH (1-84) and corresponding adjusted calcium in 
patients with HCM (•) and Paget's disease of 
bone (o) before and after APD. All results 
obtained in the study for each patient are 
plotted. The rectangle includes all 
observations within the reference range for both 
PTH (1-84) and adjusted calcium.
The mean rate of fall in adjusted Ca throughout the study 
varied between patients from 0.06 to 0.27 mmol/day (mean 
0.14) . There was no relationship between this rate of fall 
and the time after pamidronate at which serum PTH (1-84) 
became detectable.
7.1.4 Discussion
The patients with Paget's disease initially exhibited the 
expected pattern of calcium homeostasis. Therapy with 
pamidronate induced a rapid but small decrease in serum 
calcium which was sustained throughout the study. This 
effect is consistent with previous reports of pamidronate 
therapy in Paget's disease and results from reduced 
osteoclastic resorption of calcium from bone 
(267,268,269,270,271). Using the immunoradiometric assay 
for PTH (1-84), it was possible to demonstrate a 
significant increase in secretion coincident with the fall 
in serum calcium. The concentration of PTH (1-84) rose 
progressively during pamidronate therapy, despite the fact 
that the serum calcium did not continue to fall after day 
2 and despite the fact that no patient became frankly 
hypocalcaemic.
This increased secretion of PTH (1-84) following 
pamidronate therapy of Paget's disease could also be 
detected by measurement of indirect parameters of PTH 
action. PTH acts via a renal tubular receptor and cAMP 
second messenger to reduce the maximal tubular reabsorption
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of phosphate (TmP04) . Thus, the findings of decreased serum 
phosphate, decreased TmP04/GFR and increased NcAMP following 
pamidronate therapy are consistent with the known 
biological effects of increased PTH (1-84) secretion 
(46,281).
Patients with HCM showed the expected combination of 
hypercalcaemia and suppressed PTH (1-84) prior to 
pamidronate therapy. However, the pretreatment
concentrations of TmP04/GFR and NcAMP were decreased and 
increased, respectively. Such observations are consistent 
with the recognised excretion in a proportion of these 
patients of PTHrP, a molecule that is structurally distinct 
from PTH but which contains a striking homology in the N- 
terminal amino acid sequence and so binds to the renal 
tubular PTH receptor (77,78,79).
Pamidronate therapy to the patients with HCM produced the 
expected sharp and prolonged decrease in serum adjusted Ca 
(272,273,274,275,276). At the end of the study, the mean 
calcium was within the reference interval with the range of 
patient values from 2.25-2.80 mmol/L. Therefore, this 
study confirms the effectiveness of pamidronate as a 
therapeutic agent in HCM. Of particular interest, however, 
were the PTH (1-84) results, for these showed a significant 
rise on day 4 and a continuing increase to a mean 
concentration above the reference interval. The initial 
increase in PTH (1-84) occurred at a time when the mean
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serum calcium was above the reference interval, and the 
highest PTH (1-84) concentrations above the reference range 
occurred when the mean serum calcium was within the 
reference interval with no subject hypocalcaemic. This 
current data contrasts with a previous report that PTH 
secretion only occurs as patients become hypocalcaemic 
(279) . The data strongly suggest a resetting of the 
'trigger point' for PTH (1-84) secretion in patients with 
HCM. The concept of an altered 'trigger point' for PTH (1- 
84) secretion may explain a number of conditions related to 
altered calcium homeostasis (282). Previous studies using 
acute changes in calcium have shown both rate of change and 
direction of change to be important determinants of the PTH 
response in normal subjects and patients with secondary 
hyperparathyroidism (283,284) . However, the data from this 
study indicate that in HCM the absolute calcium
concentration is more important in 'triggering' PTH (1-84) 
secretion than the rate of fall in calcium that can be 
obtained following pamidronate therapy. The major clinical 
implication for these results is related to the
interpretation of PTH (1-84) concentrations in patients 
receiving pamidronate therapy. Confusion between the two 
major causes of hypercalcaemia (1°HPT and malignancy) will 
occur if a sample is obtained after treatment of 
hypercalcaemia, as in some cases of HCM modest lowering of 
Ca results in PTH (1-84) becoming detectable. It is clear 
that a valid diagnosis will only be made on a sample taken
prior to any treatment being given.
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The observed changes in TmP04/GFR and NcAMP following 
treatment of HCM with pamidronate require careful 
interpretation. If PTHrP is responsible for the abnormal 
pretreatment concentrations of these parameters in some 
patients, then the exacerbation of the abnormality 
(decreasing TmP04/GFR; increasing NcAMP) from days 2-5 after 
pamidronate may suggest increased secretion of PTHrP at 
this time, either as a direct consequence of the therapy or 
as a manifestation of the natural history of the disease. 
The paradoxical increase in TmP04/GFR and decrease in NcAMP 
on day 7 is especially interesting, as it occurs at a time 
of increasing PTH (1-84) secretion and is suggestive of 
decreased stimulation of the renal tubular PTH receptor.
This study was performed prior to the availability of 
validated assays for measurement of PTHrP (Chapter 8) and 
so the explanation of the results for NcAMP and TmP04 cannot 
be as comprehensive as one would wish. In recent studies, 
where PTHrP has been measured following pamidronate 
therapy, there has been little or no change in PTHrP 
concentrations in the week following treatment 
(285,286,287). These results may reflect differences in 
patient selection since the most recent studies have in the 
main analysed data on patients who had significantly 
elevated PTHrP levels and hypercalcaemia. Further
investigation will be required to explain the NcAMP and 
TmP04/GFR results obtained in this current study.
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Chapter 8
Parathyroid Hormone Related Protein 
and Cyclic Adenosine Monophosphate
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8.1.1 Introduction
Hypercalcaemia is a common finding in clinical practice and 
has many possible causes (75). The important differential 
diagnosis is between primary hyperparathyroidism (1°HPT) 
and hypercalcaemia associated with malignancy (HCM). 
Modern immunometric assays for PTH have the sensitivity and 
specificity to distinguish 1°HPT from non parathyroid 
causes of hypercalcaemia (100,101,129). It has been known 
for some time that certain malignancies are associated with 
the production of a humoral factor that has very similar 
properties and actions to PTH. This factor can cause 
hypercalcaemia, hypophosphataemia, increased nephrogenous 
cyclic adenosine monophosphate (NcAMP), renal conservation 
of calcium, phosphaturia and stimulate osteoclast 
activation (73,78,288). The term humoral hypercalcaemia of 
malignancy (HHM) was adopted to describe the syndrome of 
HCM in association with the cardinal features of an 
elevated NcAMP and a low or undetectable PTH (289) . In the 
late 1980s the humoral factor responsible for HHM was 
cloned, sequenced and purified and because of the 
remarkable N-terminal sequence homology with PTH was named 
Parathyroid Hormone-Related Protein (PTHrP) (79,80). 
Immunoassays have recently been developed to measure PTHrP 
and several in-house methods have been described which 
provide direct evidence for the role of PTHrP in HHM 
(247,249,290) . These assays also offer the potential value 
of diagnosing malignancy in those hypercalcaemic patients 
where the PTH (1-84) measurement is low or undetectable.
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In this chapter the clinical value of first commercial 
assay available for the measurement of PTHrP the Nichols 
Institute (Allegro) PTHrP assay has been evaluated and the 
relationship of PTHrP with NcAMP investigated.
8.1.2 Subjects and Methods
Four subject groups were studied, (i) 31 normal volunteers, 
all fit, healthy, ambulant subjects, normocalcaemic not 
taking any medication known to affect calcium metabolism 
(mean age 32, range 19-60, female 11, male 20) (ii) 29 fit 
ambulant elderly subjects (mean age 76 years, range 60-88, 
female 17, male 12) (iii) 20 patients with 1°HPT (mean age 
58, range 38-75, female 12, male 8) (iv) 95 patients with 
HCM (mean age 61, range 42-85, female 39, male 46) . All 
patients with hypercalcaemia had an elevated adjusted serum 
calcium (>2.7 mmol/L) on more than one occasion. 1°HPT was 
diagnosed by the presence of hypercalcaemia and a serum PTH 
(1-84) concentration greater than 3.0 pmol/L in all cases, 
surgical removal of a parathyroid adenoma in 10 cases and 
evidence of an adenoma on technetium/thallium subtraction 
scan in 9 cases. In 88 patients with malignant disease the 
primary tumour was identified by a combination of 
radiology, surgery and histology; in 7 patients the primary 
tumour was not identified. Bone metastases were diagnosed 
by the presence of characteristic lesions that showed 
increased tracer uptake in radionuclide bone scans; 
however, not all patients had bone scans performed.
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All subjects studied had venepuncture performed between 
10 0 0 and 12 0Oh. Serum was obtained within 3 0 min for PTH 
(1-84) assay, Li Heparin plasma for calcium, phosphate, 
creatinine, albumin measurement, EDTA plasma for cAMP 
measurement and all samples for PTHrP estimation were 
collected into vacutainer tubes supplied by Nichols 
Institute containing aprotinin (500 kallikrein units/L), 
leupeptin (5 mg/L), Pepstatin (5 mg/L) and EDTA (100 
mmol/L). Serum and plasma were stored at -70°C prior to 
hormone and cAMP assay. A 2-3h timed urine (0900-1300) was 
obtained on all normal volunteers, all 1°HPT patients and 
61 patients with malignancy (urine was not available on all 
patients with malignancy due to the severity of illness in 
some patients).
PTH (1-84) was measured using an IRMA kit (Nichols 
Institute, San Juan Capistrano, CA) , PTHrP using an IRMA 
kit (Nichols Institute, San Juan Capistrano, CA) , plasma 
cAMP using a commercial RIA kit (Amersham International, 
Bucks) , urine cAMP by an in-house RIA (Chapter 2) and NcAMP 
calculated by the method described by Broadus et al (46). 
Plasma calcium, phosphate, creatinine, albumin and urine 
creatinine were measured by standard automated methods 
(Technicon Tarrytown). Calcium was adjusted for albumin as 
described by Gardner et al (106). PTHrP and PTH peptides 
used in interference and recovery experiments were obtained 
from Peninsula (Peninsula Laboratories Europe Ltd, St 
Helens, Merseyside, UK).
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8.1.3 Results
Specificity of the PTHrP IRMA was assessed by the addition 
of human PTH (1-34) and PTH (1-84) in 10, 100 and 1,000
pmol/L concentration. No cross reactivity or assay 
interference was observed. The assay does not recognise 
human PTHrP (1-34) fragments.
Parallelism of the assay was assessed by dilutions of 3 day 
and 7 day human keratinocyte culture medium, known high 
patient PTHrP samples and a spiked (PTHrP (1-86)) low 
plasma pool. The results are shown in Table 11.
Replicate analysis of the zero standard defines the 
sensitivity of this assay as 0.3 pmol/L. A precision 
profile obtained using 6 assays is given for comparison 
(Figure 32) . Using the 22% CV as an estimate of assay 
sensitivity (98) a value of 0.7 pmol/L is obtained.
The degradation of PTHrP observed in plasma when no 
protease inhibitors were included in the collection tubes 
is shown Table 12.
Figure 33 shows the PTHrP and PTH (1-84) results obtained 
in all subjects studied comparing normals against patients 
with 1°HPT and HCM. PTHrP was greater than the detection 
limit of 0.7 pmol/L in 78% of normals and a reference range 
of <0.7-2.6 pmol/L has been established by calculating the 
95% reference interval for the values obtained in these 
subjects. All ambulant elderly patients had detectable
141
Sample Dilution Observed
(pmol/L)
Plasma Undil 8.4
1:2 4.2
1:4 2 . 0
1:8 1.1
1:16 0.6
Plasma Undil 13 .3
1:2 6.4
1:4 3.4
1:8 1.4
1:16 0.9
Keratinocyte Undil >44 . 0
Fluid (3 day) 1:5 26.0
1:10 14 . 0
1:20 6.1
Keratinocyte Undil 6.7
Fluid (7 day) 1:5 1.4
1:10 0.6
1 :20 <0.3
Spiked plasma Undil 50.0
(PTHrP (1-86)) 1:2 26 . 0
1:4 13 .4
1:8 7.6
1:16 3.5
1 :32 1.6
PTHrP Concentration 
Corrected for Dilution
(pmol/L)
8.4
8.4 
8 . 0 
8.8 
9.6
13 .3 
12 . 8 
13.6 
11.2
14 .4
>44 . 0 
130.0 
140 . 0 
122 . 0
6.7 
7.0 
6 . 0
50 . 0
52 . 0
53 . 6 
60.8 
56.0 
51.2
Table 11 Parallelism of PTHrP Assay
(%) 
A
O
26 1 
24 -
22 -
20 -
18 -
16 -
14 -
12 -
10 -
22% CV
TOTAL ERROR
MEASURING ERROR
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2 100.5 1 50
PTHrP (pmol/l)
Figure 32 Precision profile of Nichols Institute PTHrP 
assay
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PTHrP values (range 0.7-2.8 pmol/L, mean 1.7 pmol/L) , but 
these were not significantly different from values for the 
"young normal" subjects (range <0.7-2.5 pmol/L).
The distribution of PTHrP results in patients with HCM 
subdivided into tumour type is shown in Figure 33. Table 
13 gives the histological diagnosis in each patient.
The relation between PTHrP concentrations (values above the 
detection limit) and NcAMP or adjusted Ca is shown in 
Figure 34. A significant correlation exists between PTHrP 
and NcAMP (r=0.63/ p<0.01) and a weak correlation between 
PTHrP and adjusted calcium (r=0.46/ p=0.01). The
correlation was poor between PTHrP and serum phosphate 
(r=0.28/ p=0.10)/ total alkaline phosphatase (r=0.35,
p=0.05), serum creatinine (r=-0.19, p=0.28)/ and creatinine 
clearance (r=0.21, p=0.14).
NcAMP was measured in 61 patients with HCM. 12 had low or 
undetectable NcAMP (<10 nmol/L GF) , leaving 49 patients 
classified as having HHM. Of these 49, 24 had above-normal 
PTHrP with low or undetectable PTH (1-84) , 13 had
detectable PTHrP with low or undetectable PTH (1-84) , 4 had 
above normal PTHrP with above-normal PTH (1-84) and 8 had 
low or undetectable PTHrP and PTH (1-84). A sub group of 
patients is shown in Table 14 in whom the NcAMP value is 
inappropriate for the calcitropic hormones PTHrP and PTH 
(1-84). The histological diagnosis is given for each 
patient and it can be seen that a high percentage of these
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Figure 3 3 PTHrP and PTH (1-84) in normal subjects,
patients with 1°HPT and HCM. The HCM patients 
have been divided into broad groups based on the 
primary source of tumour.
Tumour Type Histological diagnosis Elevated
PTHrP
Lung (n = 26) 12/26 46%
Squamous Carcinoma 9/14 64%
Small Cell Carcinoma 0/7 0%
Adenocarcinoma 1/2 50%
Unknown 2/3 67%
Breast (n=ll) 8/11 73%
Ductal Carcinoma 3/4 75%
Lobular Carcinoma 5/6 83%
Papillary Carcinoma 0/1 0%
Genito Urinary 9/14 64%
(n=14) Carcinoma Cervix 1/1 100%
Carcinoma Ovary 0/1 0%
Carcinoma Kidney 1/3 33%
Transitional Cell 
Carcinoma Kidney
0/1 0%
Hypernephroma 
Transitional Cell
4/4 100%
Carcinoma Bladder 1/2 50%
Carcinoma Prostate 2/2 100%
Gastrointestinal 5/15 33%
(n=15) Adenocarcinoma Colon 0/5 0%
Adenocarcinoma Stomach 0/1 0%
Carcinoma Stomach 2/2 100%
Carcinoma Oesophagus 2/3 67%
Poorly Differentiated 
Carcinoma Oesophagus
0/1 0%
Somatostatinoma Pancreas 1/1 100%
Carcinoma Rectum 0/2 0%
Haematological 4/14 29%
(n=14) Myeloma 4/9 44%
Lymphoma 0/3 0%
Leukaemia 0/2 0%
Ear Nose Throat 3/7 43%
(n=7) Squamous Carcinoma Larynx 3/3 100%
Anaplastic Carcinoma Larynx 0/2 0%
Squamous Carcinoma Tongue 0/1 0%
Squamous Carcinoma 
Hypopharynx
0/1 0%
Others, unknown 3/8 38%
(n=8) Melanoma 0/1 0%
Adenocarc inoma 0/3 0%
Poorly differentiated 
Carcinoma
0/1 0%
Squamous Carcinoma 3/3 100%
Table 13 Tumour analysis in Patients with HCM
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Figure 34 Linear regression of PTHrP and NcAMP and PTHrP 
and adjusted calcium in patients with HCM.
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patients (62.5%) have small cell carcinoma of lung.
8.1.4 Discussion
PTHrP was elevated in a high percentage of patients with 
solid tumours and in those patients with tumours associated 
with HHM. These results add further weight to rapidly 
accumulating data on the role of PTHrP as a mediator of 
HHM. In patients with squamous cell carcinomas 68% had 
elevated PTHrP, in keeping with recent findings 
(247,248,249) and in patients with breast carcinoma 73% had 
elevated PTHrP as was predicted using indirect measurements 
of PTHrP action (291) and has been shown in more recent 
studies using PTHrP measurements (292) . Malignancies of 
the genito-urinary tract gave elevated PTHrP if the kidney 
or prostate was the primary tumour source and we rarely 
found elevated PTHrP in gastrointestinal malignancies or 
haematological malignancies. The differences in the 
percentage elevation found between reported studies will 
undoubtedly reflect the patient population studied and the 
tumour histology. Comparison of this HCM population 
studied with that of previous publications (249,290) 
indicates that this study had a greater percentage of 
gastrointestinal, haematological, and head and neck 
malignancies but a lower percentage of breast and 
gynaecological malignancies. The percentage of squamous 
carcinomas in this study population was also lower than in 
the previous studies. These results show elevations of 
PTHrP in a lower percentage of patients than has been
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reported in some published assays and may reflect a number 
of important problems, apart from patient selection, in the 
measurement of PTHrP.
An important observation is that PTHrP was detectable in 
some 78% of normals sampled. This normal population 
reflected a broader spectrum of subjects than previous 
studies and contained a more representative percentage of 
normal elderly subjects who are likely to be the age group 
who have malignant disease. These data and that of Pandian 
and his colleagues (249) demonstrate that PTHrP is unstable 
in plasma and must be collected into tubes with protease 
inhibitors. When samples are properly collected PTHrP is 
measurable in a high percentage of healthy subjects. These 
findings indicate that PTHrP is circulating in normal 
individuals and may have a role in calcium and phosphate 
homeostasis.
It is also possible that the assay for PTHrP is being 
affected by non specificity and matrix effects which has 
resulted in an increased detection of PTHrP in normals. 
Such effects can often cause positive bias and interference 
in immunoassays and are more often observed close to the 
detection limit of the assay. Against this possibility is 
the evidence that PTHrP has been detected and measured in 
other assays in normals and the average concentration 
observed is close to 1.0 pmol/L. However further work is 
required to fully investigate the possibility of matrix
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effects possibly using affinity chromatography of samples, 
charcoal extraction and antibody blocking tubes.
An important component of the validation of any PTHrP assay 
is the association between NcAMP production and PTHrP 
concentration. NcAMP has been used as one of the main 
indirect indicators of PTH (1-84) and PTHrP activity. 
Classification of patients with HCM based on NcAMP has been 
advocated in the past (73,288); thus it would be expected 
that PTHrP should correlate with PTHrP. The cross
correlation analysis of PTHrP above the reference range and 
NcAMP was excellent, further validating the value of this 
assay and confirming the role of PTHrP in the syndrome of 
HHM. In the patients in whom we measured all three
variables, an elevated PTHrP and a low or undetectable PTH 
(1-84) were associated with an inappropriate or elevated 
concentration of NcAMP, ranging from 14.1 to 105.6 nmol/L 
GF.
A subgroup of patients with low PTHrP and low or 
undetectable PTH (1-84) with inappropriate or elevated 
NcAMP was detected. In these patients a factor which is 
not detected as PTHrP or PTH (1-84) which is capable of 
stimulating NcAMP production and causing hypercalcaemia may 
be produced. Alternatively these patients may be producing 
an active fragment of either PTHrP or PTH which is not 
detected by the IRMA assays due to the size of the 
fragments. A less likely possibility is that another new
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molecule is being produced that has a hypercalcaemic action 
and can stimulate NcAMP production. It is interesting that 
small cell carcinoma of lung is very prevalent in this 
group of patients as a recent publication (293) has 
suggested that all major lung cancer cell types can produce 
PTHrP and that small cell lung cancer cell lines produce 
PTHrP whose molecular weight is 3,500. A PTHrP molecule of 
this size would not be measured in this assay and it is 
possible that other patients studied have tumours which 
may, by a mechanism of post translational processing, 
produce PTHrP of varying sizes. Such results also 
emphasise the continuing importance of NcAMP measurements 
when studying this group of patients and evaluating PTHrP 
assays.
At present, due to its poor specificity, PTHrP has no role 
in detecting patients with malignant disease prior to 
developing hypercalcaemia. In those patients with proven 
malignancy who were normocalcaemic only 15% had elevated 
plasma PTHrP. This is in keeping with previous reports of 
elevated NcAMP in groups of normocalcaemic patients with 
lung neoplasms and mixed neoplasms (288) .
PTHrP was elevated in 1 patient with 1°HPT who to date has 
no evidence of having a malignancy. This result is 
consistent with the findings of other groups and suggests 
that although PTHrP DNA and mRNA may be present in 
parathyroid adenomas (241,243) the production of PTHrP by
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this tissue is insufficient to elevate circulating PTHrP in 
most patients with 1°HPT. The incidence of simultaneous 
1°HPT and malignancy in this study is higher than had 
previously been reported or expected (294,295) and is in 
keeping with recent findings (247,248,249). Such an 
association is of clinical importance as treatment of both 
the condition and the hypercalcaemia would be influenced by 
the diagnosis. This data also emphasises the importance of 
obtaining samples for PTH (1-84) estimation prior to 
treatment of hypercalcaemia as lowering the calcium can 
result in an increase of PTH (1-84) prior to restoring 
normocalcaemia which could result in diagnostic confusion 
(Chapter 7).
These results indicate the value and limitations of this 
new PTHrP assay in investigating patients with 
hypercalcaemia. The assay will confirm the presence of 
PTHrP-producing tumours in a high percentage of patients 
with hypercalcaemia. An increase of PTHrP may help 
indicate the likely type of tumour present and the possible 
primary source of tumour. Treatment of hypercalcaemia may 
be influenced by the finding of an increased PTHrP since 
bisphosphonate treatment, whilst the best therapy available 
(296), is now known to be less effective in patients with 
HCM and PTHrP secretion (297). The combination of antibody 
specificities and assay technology means that circulating 
forms of PTHrP smaller than PTHrP (1-72) will not be 
detected, so that the percentage of PTHrP-producing tumours
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may be underestimated. NcAMP remains an important 
measurement in such patients and will continue to provide 
information on the factors responsible for HHM. PTHrP 
results obtained by this assay suggest that PTHrP may be 
degraded in plasma by proteases; therefore, inhibiting 
these enzymes may allow detection of PTHrP in normal 
subjects. This possibility is of obvious importance and 
requires further research and validation using alternative 
assays before the true significance of the finding will be 
known.
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Chapter 9
Cyclic AMP Production in-vitro Studied 
Using Superfusion of Rat Renal Tubules
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9.1.1 Introduction
Superfusion of dispersed cells is a technique that has been 
used to study the production and direct action of many 
hormones at the cellular level (204,298,299,300). Such a 
technique overcomes several of the problems of static 
systems and results in improved sensitivity, reduces the 
possibility of accumulation of products or metabolites and 
will minimise possible unwanted effects such as negative 
feedback of end organ response or degradation of the 
molecule of interest. The methods also allow assessment of 
dose response effects and the efficacy of inhibition using 
the same tissue preparation over a short period which will 
minimise biological variation. A modification of the 
method established by Lowry and McMartin (204) has been 
developed to study dispersed rat adrenal cells using a 
column superfusion technique (301) which is readily 
adaptable to other cell types.
The biological activity of PTH can be quantified in terms 
of cAMP production by kidney cells either in-vivo or in- 
vitro (43,46,54,55,67). Stimulation of the kidney or renal 
cells by PTH has been investigated for many years and cAMP 
production by the kidney forms the basis of an important 
diagnostic test for pseudohypoparathyroidism (43,55). 
Renal tubular cells would therefore appear to be suitable 
candidates for studying the effects of PTH on cAMP 
generation by superfusion techniques.
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Opinion has varied concerning the effect that acidosis can 
have on PTH action at both kidney and bone. Some authors 
claim that PTH action, assessed by UcAMP excretion or 
tubular reabsorption of phosphate or urinary calcium 
excretion, is inhibited in acute and chronic metabolic 
acidosis in rats or dogs (164,165) and that this 
contributes to the metabolic bone disease that occurs in 
renal failure. Others have failed to confirm this 
conclusion and have argued that prolonged metabolic 
acidosis has little or no effect on bone or renal 
responsiveness to PTH in man (302) and the actions of PTH 
are not impaired during chronic metabolic acidosis in dogs 
(303) . In some studies acute metabolic acidosis has 
enhanced PTH action with increased cAMP production by 
isolated perfused dog bone (163) and increased NcAMP 
production in rats made acutely acidotic (304).
Alkalosis has little effect on the biological actions of 
PTH investigated to date although chronic metabolic 
alkalosis in rats results in an increased circulating PTH 
but no change in total serum calcium and a decrease in 
ionised calcium (305) . Inducing acute alkalosis in rats 
has no effect on the tubular reabsorption of phosphate in 
response to PTH (164) nor any effect on the change in serum 
calcium concentrations following PTH injection (306) .
In human studies that have been performed it has been 
demonstrated that arginine hydrochloride can block the
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action of PTH on the renal tubule resulting in a 
significant decrease in UcAMP production (307). This 
effect if confirmed may be important for patients receiving 
parenteral nutrition where arginine can form a major 
component of the infusion. In patients on long term 
parenteral nutrition arginine infusion may result in 
inhibition of PTH action at the kidney and contribute to 
the metabolic bone disease observed in these patients. 
Since the superfusion technique is an ideal system for 
studying the effects of changing an individual component of 
the perfusate on biological activity this technique was 
adapted to study factors that may influence the production 
of cAMP by rat renal tubules in response to PTH 
stimulation.
9.1.2 Materials and Methods
Each superfusion experiment was performed using the kidneys 
obtained from 2 adult male Wistar rats (200-250 g) killed 
by cervical dislocation. Renal cortical tissue was 
dissected from the kidney, after removal of the capsule, 
and then minced using a scalpel and scissors. This tissue 
was then digested with 10 ml of enzyme solution (0.05% 
collagenase) (Worthington Biochemical Corporation, 
Freehold, NJ, U.S.A.) and 0.1% hyaluronidase (Sigma 
Chemical Company Ltd, Poole, Dorset, U.K.) in a Hepes-based 
collagenase buffer (Table 15) for 60 min in total at 37°C. 
The supernatant was removed after 3 0 min and the remaining 
cortical tissue mechanically dispersed with a pipette into
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Collagenase Buffer Concentrate
NaCl 4.0 g
KCl 0.5 g
CaCl2 2H20 0.7 g
HEPES 24.0 g
1M NaOH 66 ml
H20 100 ml
Collagenase 0.5 g
5 ml aliquots were stored at -50°C. Each aliquot was 
diluted 1/10 prior to use in distilled H20 with 2% BSA.
Superfusion/Suspension Buffer
Three separate concentrated buffers were combined together 
when required composed of 5 ml A, 5 ml B and 10 ml C made 
up to 100 ml with distilled H20 containing 0.2% BSA with 4% 
glucose.
A Calcium/Magnesium Concentrate
MgCl2 6H20 0.52 g
CaCl2 2H20 0.72 g
H20 200 ml
5 ml aliquots were stored at -50°C.
B Calcium Concentrate
CaCl2 2H20 1.8 g
H20 200 ml
5 ml aliquots were stored at -50°C.
C Suspension Buffer Concentrate
NaCl 16 . 0 g
KCl 1.6 g
kh2po4 0.6 g
Na2S04 0.4 g
HEPES 28.8 g
TES 27.6 g
Tricine 26.0 g
NaOH 8.4 g
H20 400 ml
10 ml aliquots were stored at -50°C.
Table 15 Composition of buffers used in preparing renal 
tubules and in superfusion experiments
10 ml fresh enzyme solution for a further 3 0 min digestion 
at 37°C. The resultant suspension of isolated cortical 
tubules was filtered through nylon mesh (100 /x m) and 
centrifuged at 300 g for 10 min. Pellets obtained were 
resuspended in 10 ml Hepes-based superfusion buffer (Table 
15) and the washing procedure repeated twice. The final 
tubule pellet was resuspended in 2-3 ml superfusion buffer 
and a tubule count performed using a Buchner 
Haemocytometer. Viability of the tubules was assessed 
using the Typan Blue exclusion technique. An identical 
volume of tubule preparation was introduced onto the top of 
especially designed Teflon columns (301). 4 columns were
run simultaneously. The tubules were retained on top of 
Sephadex G50 coarse gel (Pharmacia, Milton Keynes, UK) 
which was retained by 3 0 /xm nylon gauze. A reservoir of 
Hepes-based superfusion buffer, all tubing (including a 
debubbler) and the 4 teflon columns were maintained at 37°C 
in a water bath. Fluid was pumped from the reservoir 
through the columns from top to bottom by means of a 
Technicon continuous flow pump (Technicon Tarrytown USA) 
via continuous flow tubing. The flow rate was controlled 
by altering the tubing diameter so that a rate of 6 00 
/xL/min was obtained. Effluent from the bottom of the 
columns was collected at 2 min intervals and stored at 
-20°C before analysis. The volume of effluent obtained was 
measured accurately by weighing. A line diagram of the 
perfusion apparatus outlining the components of the system 
is shown in Figure 35.
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In initial experiments to establish optimum conditions for 
stimulation all 4 columns were perfused with standard Hepes 
superfusate buffer. Subsequently 2 columns were perfused 
with standard buffer and 2 with test perfusates. The test 
perfusates contained standard Hepes based buffer 
superfusates with the addition of a) HC1 (BDH, Poole, 
Dorset, UK) to produce a pH of 7.1 b) NaOH (BDH) to produce 
a pH of 7.65 and c) arginine hydrochloride (Sigma Chemical 
Company Ltd) at a concentration of 7 mmol/L. Experiments 
were performed in the absence and presence of the 
phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) 
(Sigma Chemical Company Ltd) . IBMX was added in an attempt 
to optimise cAMP concentration by preventing 
phosphodiesterase degradation of cAMP in the eluent.
Stimulation was performed using PTH (1-84) (National 
Institute for Biological Standards, South Mimms, Potters 
Bar U.K.) or synthetic bovine PTH (1-34) (Sigma Chemical 
Company Ltd). PTH was dissolved in 0.1% acetate buffer pH 
4.0 and stored at -50°C in 100 /xL aliquots containing 250 
IU per 100 /xL. An aliquot was thawed and diluted in the 
appropriate perfusate buffer just prior to use.
Cyclic AMP was measured in an in-house radioimmunoassay 
(97) following acetylation of 500 /xL of sample with 5 /xL of 
an acetylation mixture containing 2:1 (vol/vol) 
triethylamine/acetic anhydride (BDH). This assay has a 
sensitivity of 30 pmol/L and a between batch CV of <12%
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across the range 45-400 pmol/L. The characteristics of the 
antibody have been described Chapter 2.
Cyclic AMP in the comparative experiments (pH and Arg HC1) 
was expressed as total output, which was estimated from the 
volume of effluent and concentration of cAMP obtained, per 
106 tubules per PTH pulse. Comparisons were made of the 
mean of 3 separate experiments involving four separate 
periods of stimulation with PTH. The columns were rotated 
clockwise following each experiment so that control and 
test columns varied. Statistical differences were
evaluated using Mann-Whitney U statistics for each 
experiment.
9.1.3 Results
The viability of the tubular cells as measured by the Typan 
Blue exclusion technique varied between 95-98%. Cyclic AMP 
production obtained when the tubules were allowed to 
equilibrate on the columns for 60, 90 and 180 min before
stimulation with PTH (1-84) is shown Figure 36. An initial 
dose-response study was performed which indicated that 2.5 
units of bovine PTH (1-84) would result in an accurately 
measured cAMP response from the tubules. An erratic 
production of cAMP was observed when tubules were 
equilibrated for 60-90 min, following 90 min equilibration 
a stable reproducible response was obtained. After 180 min 
equilibration cAMP output became inconsistent when 
stimulation was attempted beyond 196 min. In all
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Figure 3 6 Renal tubules stimulated with bovine PTH (1-84) 
after 60, 90 and 180 min equilibration on the 
superfusion columns. Each line represents the 
results from a single column. PTH was 
introduced as a bolus on top of the columns at 
times indicated by the arrows.
subsequent experiments the tubules were allowed to 
equilibrate on the columns for 90 min before stimulation 
experiments were performed. Figure 3 7 shows the cAMP 
produced by the tubules when stimulated by bovine PTH (1- 
84) in the presence and absence of 1 mM of the 
phosphodiesterase inhibitor iso-butyl-methylxanthine (IBMX) 
and when unstimulated with IBMX present. For all 
subsequent experiments 1 mM IBMX was added to the 
superfusion buffer. The responses to repeated stimulation 
for 75 min after 90 min equilibration on the columns are 
shown Figure 38. Comparison of the tubule responses from 
2 columns stimulated in an identical manner are shown 
Figure 3 8a for control v stimulated and 3 8b for 2 columns 
stimulated with PTH.
Figure 3 9 shows the dose response curves obtained for 
tubule stimulation using bovine PTH (1-84) and synthetic 
bovine sequence PTH (1-34). An equivalent response to both 
molecules is observed over the range of concentrations 
studied and the response is consistent and reproducible 
over three experiments.
Figures 40, 41 and 42 show the tubule responses obtained
when perfusion was performed with buffer at pH 7.4, pH 7.1 
(Figure 40), pH 7.4, pH 7.65 (Figure 41) and 7 mM arginine 
hydrochloride compared to control (Figure 42) . Table 16 
gives the mean values obtained and the statistical 
comparisons between each group of experiments. There is a
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Figure 37' Renal tubules stimulated with bovine PTH (1-84) 
in the presence and absence of IBMX. Each line 
represents the results from a single column. 
PTH was introduced as a bolus on top of the 
columns at times as indicated by the arrows.
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Renal tubules repeatedly stimulated with bovine 
PTH (1-84) after 90 min equilibration on the 
superfusion columns a) stimulated column and 
unstimulated control b) two columns stimulated. 
Each line represents the results from a single 
column. PTH was introduced as a bolus on top of 
the columns at times indicated by the arrows.
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Figure 3 9 Dose responses to bovine PTH (1-84) and 
synthetic human PTH (1-34). Each line 
represents the results from a single column 
PTH was introduced as a bolus on top of the 
columns at times indicated by the arrows.
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Figure 4 0 Comparison of cAMP production by renal tubules 
in response to stimulation with bovine PTH 
(1-84) when perfused at pH 7.4 or pH 7.1. Each 
line represents the results from a single 
column. PTH was introduced as a bolus on top of 
the columns at times indicated by the arrows.
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Figure 41 Comparison of cAMP production by renal tubules 
in response to stimulation with bovine PTH 
(1-84) when perfused at pH 7.4 or pH 7.65. Each 
line represents the results from a single 
column. PTH was introduced as a bolus on top of 
the columns at times indicated by the arrows.
1cAMP
nmol/L
PTH Bolus
2.5 Units
Figure 42
8
4
0
50 604020 300 10
Control 
7mM Arg HCI
Time (min)
Comparison of cAMP production by renal tubules 
in response to stimulation with bovine PTH 
(1-84) when perfused in the presence or absence 
of 7mM Arg HCI. Each line represents the 
results from a single column. PTH was 
introduced as a bolus on top of the columns at 
times indicated by the arrows.
Conditions for 
Perfusion
Mean cAMP output fmol/106 Significant 
renal tubules/pulse Difference
Control (1) pH 7.4 
pH 7.1
55.2 ± (14.9) 
36.9 ± (13.1)
p < 0.01
Control (2) pH 7.4 
pH 7.65
51.2 ± (10.2) 
49.9 ± (10.3)
NS
Control (3) pH 7.4 
7 mM Arg HCI present
53.6 ± (8.8) 
45.1 ± (9.3)
p < 0.05
Mean + SD
Table 16 Comparison of cAMP Production by Superfused Renal 
Tubules pulsed with PTH whilst perfused at 
pH 7.4, pH 7.1, pH 7.65 and in the presence or
absence of 7mM Arc HCI
statistically significant decrease in cAMP output in 
response to bPTH (1-84) when the tubules are exposed to the 
acidic perfusate but not the alkaline perfusate. A 
statistically significant decrease in cAMP output in 
response to bPTH (1-84) is also noted when the tubules were 
perfused with arginine hydrochloride.
9.1.4 Discussion
In these experiments it has been demonstrated that 
superfusion of rat renal cortical tubules can be used to 
study the factors affecting cAMP production by renal 
tubules in response to bPTH (1-84) stimulation. This 
system has the advantage that the biological activity of 
PTH can be assessed in a consistent reproducible manner, 
after 90 min equilibration of the tubules on the columns, 
as demonstrated by both bPTH (1-84) and hPTH (1-34) 
fragment stimulation. By running control experiments in 
parallel with the test columns the effects of changing 
individual factors in the perfusate are readily observed 
and any unexpected effects or perturbations of the 
experimental system are immediately obvious.
Although the superfusion technique is not a physiological 
system it has many advantages over other in-vitro bioassay 
systems most of which will also require the use of 
supraphysiological doses of hormone. The superfusion 
system responses to increasing doses of both bPTH (1-84) 
and hPTH (1-34) were consistent, linearly increased over
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the concentration ranges studied and are reproducible. 
There was an indication that under current conditions the 
tubule response diminished with the length of time the 
cells were on the columns which may reflect a number of 
factors. Obvious explanations may be that the cell 
receptors may down regulate on repeated stimulation, 
receptor cycling may slow down, precursors for cAMP 
generation may be gradually diminished, there may be an 
insufficient energy supply for the cells and the number of 
functioning tubules may decrease with time.
A significant decrease in cAMP production by the tubules in 
response to bPTH (1-84) was noted when they were perfused 
with acidic buffer (pH 7.1) . This effect has occurred 
acutely and persisted throughout the period of perfusion of 
the tubules. This down regulation of response to PTH may be 
due to acidosis affecting the tubular cells such that 
receptor function changes or receptor cycling is slowed 
down or possibly due to effects of the acidic environment 
on the PTH molecule itself. Conflicting evidence exists in 
the literature on the effects of changes in acid-base 
status on PTH action at both bone and kidney and reflects 
the fact that different animal species have been studied, 
different cell systems have been used and different methods 
have been adopted to induce acidosis or alkalosis. 
Experiments using rats have detected a decrease in UcAMP 
production, decreased adenylate cyclase activity and 
decreased P04 excretion in animals made acutely acidotic
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(164) . The response to PTH injection was also reduced with 
decreased UcAMP production, reduced phosphaturic effect and 
increased urinary Ca excretion (164,306). However, after 
a period of prolonged acidosis in man and dogs there has 
been no impairment observed in PTH effects as assessed by 
urinary calcium, phosphate, bicarbonate excretion and by 
changes in circulating ionised calcium (302,303). In dogs 
made acutely acidotic cAMP production in response to PTH 
stimulation increased from perfused canine tibia (163). It 
would appear that in the intact animal changes may occur 
with time in chronic acidosis to overcome the reduced 
response to PTH we have observed in tubules made acutely 
acidotic. One way of overcoming such effects would be by 
increasing PTH secretion from the parathyroid gland and so 
chronic acidosis may result in secondary 
hyperparathyroidism.
While compensatory effects are occurring the acute effects 
of acidosis observed in these experiments may have 
important consequences for calcium homeostasis at the 
kidney and may contribute to the pathogenesis of metabolic 
bone disease observed in acidotic patients.
Perfusion of the tubules with alkalotic buffer had no 
measurable effect on the production of cAMP by renal 
tubules. This result is in keeping with previous data 
where intact animals have been made acutely alkalotic 
(164,306). Chronic metabolic alkalosis in rats results in
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several changes in calcium metabolism. A decrease in 
ionised calcium and an increase in PTH are the most obvious 
effects. An appropriate response to this increased PTH is 
observed in chronic alkalosis with increased 1,25 (OH)2D3, 
phosphaturia and hypocalciuria (305). Taken together with 
the current data these results indicate that neither acute 
nor chronic alkalosis interferes with PTH action at the 
tubule.
Arginine hydrochloride has been used in clinical medicine 
to treat severe metabolic alkalosis, diagnose growth 
hormone deficiency and investigate insulin release. 
Infusion of arginine hydrochloride into healthy male 
volunteers results in a diuresis, a fall in urine 
osmolality, a decrease in free water clearance, a decrease 
in renal phosphate clearance and a decrease in UcAMP output 
(307) . The response to 230 i.u. of PTH intravenously is 
also significantly reduced during the infusion of arginine 
hydrochloride (307). In superfused tubules there is a 
significant decrease in cAMP output in response to PTH 
stimulation in the presence of arginine hydrochloride. A 
minimal decrease in pH of the perfusate is observed with 
the concentration of arginine hydrochloride used in this 
experiment and so the effect on PTH action is due to 
arginine hydrochloride. There are a number of possible 
explanations for the effect of arginine hydrochloride on 
cAMP production. Arginine is actively transported into 
renal tubular cells and the high intracellular
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concentration of arginine could inhibit the endocytosis of 
receptor-ligand complexes or receptor recycling in these 
cells. Arginine may block the action of PTH at its 
receptor by occupying the receptor binding site. 
Biological activity of PTH resides in the first 1-34 amino 
acids of the polypeptide, a sequence which contains three 
lysine and two arginine residues. The minimum polypeptide 
required for biological activity is the 2-25 N-terminal 
sequence which contains two arginine and one lysine 
residues. PTHrP also has a similar number of arginine and 
lysine residues in both the 1-34 (5) and 1-84 (14)
peptides. Cyclohexanedione modification of arginine 
residues blocks receptor mediated uptake of low density 
lipoprotein by several cells. The cumulated evidence would 
indicate that arginine plays an important role in hormone- 
receptor interaction and it is possible that exogenous 
arginine may interfere with PTH activity. This may have 
implications for patients receiving total parenteral 
nutrition (TPN). Many patients receiving TPN have 
hypercalciuria and long term may develop calcium and 
phosphate imbalance and metabolic bone disease (308). 
Amino acid infusions used in such therapy have relatively 
high concentrations of arginine and this may produce the 
effect that we have seen in the tubule superfusion 
experiments resulting in a decreased response to PTH and 
abnormal calcium/phosphate homeostasis.
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The superfusion technique is a reliable, reproducible
method for studying the direct action of PTH in terms of
cAMP production from renal tubules in isolation.
Superfusion has many similarities with the normal
physiology of the tubules, where PTH is delivered to the 
target cell via the arterial supply and cellular products 
are removed via the venous drainage and/or urine. In these 
experiments this technique has shown its value in studying 
PTH activity in-vitro and the method described will be of 
value in investigating the many factors that can alter cAMP 
metabolism in renal tubular cells.
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Chapter 10
Current and Future Research in Relation 
to the Work of This Thesis
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The importance of the circadian rhythms of the hormones 
controlling cAMP production and the alteration of cAMP 
metabolism throughout a 24h period has given new insight 
into mechanisms that could control calcium homeostasis and 
bone turnover. Further understanding of the physiological 
and pathological modification of the circadian rhythms of 
PTH (1-84) and cAMP should lead to a better understanding 
of normal bone remodelling and metabolic bone disease. 
Studies have been initiated and have produced interesting 
data on differences in the circadian rhythms of PTH (1-84) 
and NcAMP in pre-menopausal, normal post-menopausal and 
osteoporotic post-menopausal women (3 09) . The circadian 
rhythms of PTH (1-84) and NcAMP are present in pre­
menopausal women, attenuated in post-menopausal women 
without osteoporosis and absent in post-menopausal 
osteoporotic women. These findings have resulted in the 
initiation of a programme of investigation into
manipulation of the PTH (1-84) and cAMP response using
timed ingestion of calcium and phosphate (310) . The
studies in this thesis formed the basis of a theory that 
phosphate was important in the genesis of the PTH (1-84) 
circadian rhythm and by increasing ingestion of phosphate 
at 22.00 the PTH (1-84) and cAMP rhythms would be augmented 
resulting in beneficial effects on bone metabolism. 
Measurement of overnight NcAMP production, first voided 
morning urine, as a ratio against second voided urine gives 
an accurate indication of PTH (1-84) secretion overnight 
and enables a rapid assessment of the effects of different
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therapeutic manoeuvres (311)
Neuroendocrine control of the circadian rhythm of PTH (1- 
84) and subsequent cAMP production is being investigated 
using the LHRH agonist Buserelin to modify the pituitary 
production of gonadotrophins and prolactin (312) . Long 
term studies on cAMP metabolism in the "chronic fasting 
state" anorexia nervosa are planned in the light of results 
obtained from the sleep shift and fasting studies.
It will be important to investigate whether intradian 
variation (minute to minute) in PTH (1-84) will result in 
modification of the cAMP responses thus altering calcium 
and phosphate homeostasis and whether manipulation of 
calcium and phosphate concentrations can change PTH (1-84) 
and cAMP metabolism with beneficial effects on bone. 
Studies have commenced looking at the pulsatility of PTH 
(1-84) and cAMP generation in normal subjects before and 
after EDTA infusion (313), hyperparathyroid patients (314), 
fasting subjects (315) and reports of alteration in PTH (1- 
84) pulsatility in osteoporotic patients have recently been 
published (316,317). The cAMP production by cells in 
response to hormonal stimulation and subsequent cell 
function is likely to alter depending on the combination of 
intradian and circadian stimuli.
Studies in this thesis have demonstrated that cAMP 
metabolism may be affected by a number of circulating
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hormones and so interpretation of cAMP concentrations in- 
vivo requires detailed knowledge of the status of several 
hormones. There have been few attempts to study 
simultaneously hormones which affect cAMP production even 
in the short term and circadian studies on the combined 
effect of hormones on cAMP metabolism are non existent. 
Future research will attempt to isolate separate hormonal, 
particularly thyroid, cortisol and catecholamine effects 
in-vivo and in-vitro.
Development of assays for PTHrP open up major avenues of 
scientific and clinical research. Measurement of PTHrP in 
hypercalcaemia can help resolve difficult diagnostic 
problems and help in the management of patients. Recent 
data obtained using the assay evaluated in this thesis has 
indicated that elevated PTHrP in patients with HCM is 
associated with decreased survival, increased metastatic 
tumour load and increased bone turnover (318) . Responses 
to bisphosphonate therapy are poorer in patients with 
elevated PTHrP (297) and treatment regimens and therapeutic 
approaches in patients with HCM may be modified as more 
knowledge is obtained on the physiology and pathophysiology 
of PTHrP. Studies performed during and after pregnancy 
have demonstrated that PTHrP increases gradually during 
pregnancy and can become markedly elevated at the time of 
lactation (319, 320). In this situation PTHrP may be
produced by the placento/uterine and breast tissue and may 
stimulate increased bone turnover that is observed in
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pregnancy. Evidence for the role of local PTHrP production 
by osteoblasts has recently been obtained and indicates 
that an autocrine/paracrine function of PTHrP may be very 
important in maintaining normal bone and in metabolic bone 
disease (321, 322, 323).
The superfusion system successfully allowed the study of 
individual factors that can affect the production of cAMP 
by renal tubular cells. Modification of this system will 
be required to make this technique less laborious and time 
consuming with alteration of the perfusion flow rate 
possible, collection of fewer samples following 
stimulation, integrating cAMP production after each 
stimulus and supplementing the perfusate buffer to allow 
prolonged survival of the tubular cells. Commercial 
equipment has recently become available that has automated 
several of the processes employed in superfusion 
experiments which confers a greater flexibility on the 
system and would allow quicker optimisation of the 
experimental technique.
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